よくわかる悪性リンパ腫のすべて

出版社： 永井書店
著者：
発行日： 2008-09-01
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 9784815918170
電子書籍版： 2008-09-01 （第1版）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

9,350 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,675 円(税込)

購入する

商品紹介

悪性リンパ腫患者の診療の専門医はもちろんのこと、研修医、若手医師を第一の読者対象に、悪性リンパ腫という疾患と治療選択に関する理解を深めて頂くことを目的とした悪性リンパ腫の診療と研究についての本格的かつ実践的な解説書。わが国における悪性リンパ腫の診療と研究現場において第一線で活躍する医師たちが各章を担当、診療と研究の現在の到達点が詳述されている。

目次

  • よくわかる悪性リンパ腫のすべて

    ―目次―

    １　悪性リンパ腫とは何か―悪性リンパ腫の種類と分類
    ２　悪性リンパ腫はなぜ起きるのか
    ３　悪性リンパ腫の疫学
    ４　悪性リンパ腫と染色体や遺伝子の異常
    ５　悪性リンパ腫の診断に必要な検査、病期診断、治療効果判定法
    ６　悪性リンパ腫治療に使用される薬物
    ７　悪性リンパ腫の放射線治療
    ８　悪性リンパ腫の予後因子と治療選択
    ９　JCOGリンパ腫グループによる多施設共同臨床試験
    １０　臨床試験とインフォームド・コンセント
    １１　ホジキンリンパ腫の治療
    １２　濾胞性リンパ腫の治療
    １３　MALTリンパ腫の治療
    １４　マントル細胞リンパ腫の治療
    １５　中悪性度リンパ腫の治療
    １６　高悪性度リンパ腫（前駆Tリンパ芽球性リンパ腫と
    　　　　バーキットリンパ腫）の治療
    １７　末梢性T細胞リンパ腫とNK/T細胞リンパ腫の治療
    １８　成人T細胞白血病/リンパ腫の治療
    １９　高齢者悪性リンパ腫の治療
    ２０　小児悪性リンパ腫の治療
    ２１　消化管に発生するリンパ腫の治療
    ２２　脳に発生するリンパ腫の治療
    ２３　眼の周囲に発生するリンパ腫の治療
    ２４　皮膚に発生するリンパ腫の治療
    ２５　骨に発生するリンパ腫の治療
    ２６　再発、再燃悪性リンパ腫の救援化学療法
    ２７　悪性リンパ腫の自家造血幹細胞移植併用大量化学療法：
    　　　　適切な施行対象と施行時期
    ２８　悪性リンパ腫の同種造血幹細胞移植
    ２９　抗がん剤治療の副作用とその対策
    ３０　悪性リンパ腫治療中のB型肝炎ウイルス再活性化とその対策
    ３１　悪性リンパ腫治療後の晩期障害と二次癌
    ３２　悪性リンパ腫に対して開発中の新薬

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

[1] 悪性リンパ腫とは何か-悪性リンパ腫の種類と分類

P.14 掲載の参考文献
1) Jaffe ES, Harris NL Stein H, et al:World Health Organization classification of Tumours. Patphology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2001.
 
2) Hans CP, Weisenburger DD, Greiner TC, et al:Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004.
PubMed
3) Hiddemann W, Longo DL, Coiffier B, et al:Lymphoma classificatlon;the gap between biology and clinical management is closing. Blood 88:4085-4089, 1996.
PubMed

[2] 悪性リンパ腫はなぜ起きるのか

P.21 掲載の参考文献
1) Jaffe ES, Karris NL Stein H, et al:World Health Organization Classification of Tumours;Pathology & Genetics, Tumours of Hematopoietic and Lymphoid Tissues. IARC Press, Lyon, 2001.
 
2) Lymphoma study group of Japanese pathorogists:The World Health Organization classification of malignant lymphomas in Japan;incidence of recently recognized entities. Pathol Int 50:696-702, 2000.
 
3) van den Bosch CA:Is endemic Burkitts lymphoma an alliance between three infections and a tumour promoter?Lancet Oncol 5:738-746, 2004.
 
4) Stein H, Foss HD, Durkop H, et al:CD30 (+) anaplastic large cell lymphoma:a review of its histopathologic, genetic, and clinical features. Blood 96:3681-3695, 2000.
PubMed
5) Streubel B, Vinatzer U, Willheim M, et al:Novel t (5;9) (q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia 20:313-318, 2006.
PubMed
6) Kondo E, Yoshino T:Expression of apoptosis regulators in germinal centers and germinal center-derived B-cell lymphomas;insight into B-cell lymphomagenesis. Pathol Int 57:391-397, 2007.
PubMed
7) Roulland S, Navarro J-M, Grenot P, et al:Follicular lymphoma-like B celis in heaithy individuals;a novel intermediate step in early lymphomagenesis. J Exp Med 203:2425-2431, 2006.
 
8) Shimoyama Y, Sakakibara A, Kawai K, et al:Molecular diagnosis of malignant lymphoma;mantle cell lymphoma, anaplastic large cell lymphoma, and marginal zone B-cell lymphoma of MALT. Nagoya J Med Sci 68:1-8, 2006.
PubMed
9) Yatabe Y, Suzuki R, Matsuno Y, et al:Morphological spectrum of cyclin D1-positive mantle cell lymphoma;study of 168 cases. Pathol Int 51:747-761, 2001.
PubMed
10) Seto M:Genetic and epigenetic factors involved in B-cell lymphomagenesis, Cancer Sci 95:704-710, 2004.
 
11) Nakamura T, Seto M, Tajika M, et al:Clinical features and prognosis of gastric MALT lymphoma with special reference to responsiveness to H. pylori eradication and API2-MALTI status. Am J Gastroenterol 103 (1):62-70, 2008.
 
12) ParsonnetJ, Isaacson PG:Bacterial infection and MALT lymphoma. Engl J Med 350:213-215, 2004.
 
13) Oshimi K:Progress in understanding and managing natural killer-cell malignancies. Br J Haematol 139 (4):532-544, 2007.
PubMed
14) Asano N, Oshiro A, Matsuo K, et al:Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma;a clinicopathologic study. J Clin Oncol 24:4626-4633, 2006.
PubMed
15) Anderton E, Yee J, Smith P, et al:Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim:clues to the pathogenesis of Burkitt's lymphoma. Oncogene 27 (4):421-433, 2008.
 
16) Ohshima K:Pathological features of diseases associated with human T-cellleukemia virus type 1.Cancer Sci 98:772-778, 2007.
 
17) Shimoyama Y, Oyama T, Asano N, et al:Senile Epstein-Barr virus-associated B-cell lymphoproli-ferative disorders:amini review. J Clin Exp Hematop 46 (1):1-4, 2006,
 
18) Oyama T, Yamamoto K, Asano N, et al:Age-related EBV-associated B-cell lymphoproiiferative disorders constitute a distinct clinicopathologicgroup;astudy of 96 patients, Clin Cancer Res 13:5124-5132, 2007.
 

[3] 悪性リンパ腫の疫学

P.27 掲載の参考文献
1) The Research Group for Population-based Cancer Registration In Japan:Cancer incidence and incidence rates in Japan in 1995, Estimates based on data from nine population-based cancer registries. Jpn J Clin Oncol 30:318-321, 2000.
 
2) Weiss NS:Geographical variation in the incidence of the leukemias and lymhomas. Natl Cancer Inst Monogr 53:139-142, 1972.
 
3) Aozasa K, Tsujimoto M, Sakurai M, et al:Non-Hodgkin's lymphomas in Osaka, Japan. Eur J Cancer Clin Oncol 21:487-492, 1987.
 
4) The T-and B-cell Malignancy Study Group:Statistical analysis of immunologic, clinical and histopathologic data on lymphoid malignancies in Japan. Jpn J Clin Oncol 11:15-38, 1981.
 
5) Aozasa K, Ueda T, Tamai M, et al:Hodgkin's disease in Osaka, Japan (1964-1985) . Eur J Cancer Clin Oncol 22:1117-1119, 1986.
PubMed
6) Ohsawa M, Aozasa K, Tsujimura T, et al:Non-Hodgkin's lymphoma of follicular center cell type in Osaka, Japan. Eur J Cancer Clin Oncol 25:1875-1878, 1989.
PubMed
7) Miyazato H, Nakatsuka S, Miyanaga L et al:Follicular lymphoma in Osaka, Japan;Histological features and chronological change. Int J Hematol 76:333-337, 2002.
 
8) Aozasa K, Ohsawa M, Tajima K, et al:Nation-wide study of lethal midline granuloma in Japan;frequencies of Wegener's granulomatosis, polymorphic reticulosis, malignant lymphomas and other retated conditions. Int J Cancer 44:63-66, 1989.
 
9) Anderson JR, Armitage JO, Weisenburger DD:Epidemiology of the non-Hodgkin's lymohomas;distributions of major subtypes differ by geographic location. Ann Oncol 9:717-720, 1998.
 
10) Miyazato H, Nakatsuka S, Dong Z, et al:NK-cellrelated neoplasms in Osaka, Japan. Am J Hematol 76:230-235, 2004.
 
11) Jaffe ES, Harris NL, Stein H, et al (eds):Word Health Organization Classification of Tumours;Pathology&Genetics, Tumours of Hematopoietic and Lymphoid Tissues. IARC Press, Lyon, 2001.
 
12) Lymphoma Study Group of Japanese pathologists:The World Health Organization classification of malignant lymphomas in Japan;Incidence of recently recognized entities. Pathol Int 50:696-702, 2000.
 
13) The Non-Hodgkin's Lymphoma Classification Project:A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgikin's Lymphoma. Blood 89:3909-3918, 1997.
 
14) Chiu BCH, Weisenburger DD:An update of epidemiology of non-Hodgkin's lymphoma. Clin Lymph 4:161-168, 2003.
 
15) 青笹克之, 中塚伸一:EBV関連リンパ腫の病態. 分子細胞治療1:579-584, 2002.
 
16) Hoshida Y, Tsukuma H, Yasunaga Y, et al:Cancer risk after renal transplantation in Japan. Int J Cancer 71:517-520, 1997.
PubMed
17) 中塚伸一, 青笹克之:SV-40ウイルスと悪性リンパ腫, 血液・腫瘍科47:52-58, 2003.
 
18) Jaffe ES:Common threads of mucosa-associated lymphoid tissue lymphoma pathogenesis:from infection to translocation (Editorial) . J Natl Cancer Inst 96:571-573, 2004.
PubMed
19) Yakushijin Y, Kodama T, Takaoka I, et al:Absence of chlamydial infection in Japanese patients with ocularadnexal lymphoma of mucosa-associated lymphoid tissue. Int J Hematol 85:223-230, 2007.
 
20) Miligi L, Costantini AS, Bolejack V, et al:Non-Hodgkin lymphoma, leukemia, and exposure in agriculture;results from the Italian multicenter case-control study. Am J Ind Med 44:627-636, 2003.
PubMed
21) Baccareli A, Hirt C, Pasatori AC, et al:t (14;18) translocations in lymphocytes of healthy dioxin-exposed individuals from Soveso, Italy. Carcinogenesis 27:2001-2007, 2006.
 
22) Chiu BCH, Dave BJ, Biair A, et al:Agricultural pesticide use and risk of t (14;18);defined subtypes of non-Hodgkin lymphoma. Blood 108:1363-1369, 2006.
PubMed
23) Kojya S, Matsumura J, Li T, et al:Familial nasal NK/T-cell lymphoma and pesticide use. Am J Hematol 66:145-147, 2001.
 
24) Xu JX, Hoshida Y, Yang Wl, et al:Life-style and environmental factors inthe development of nasal NK/T-cell lymphoma;A case-control study in East Asia. Int J Cancer 120:406-410, 2006.
 
25) Floret N, Mauny F, Challier B, etal:Dioxin emissions from a solid waste incineratorand risk of non-Hodgikin:s lymphoma. Epidemiol 14:392-398, 2003.
 
26) Thomas E, Brewster DH, Black RJ, et al:Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88:497-500, 2000.
PubMed
27) Wolfe F, Michud K:Lymphoma in rheumatoid arthritis;The effect of methotrexate and anti-tumor necrosis factor therapy in 18, 572 patients. Arthritis Rheum 50:1740-1751, 2004.
 
28) Hoshida Y, Xu JX, Fujita S, et al:Lymphoproliferative disorders in rheumatoid arthritis;Clinico-pathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 34:322-331, 2007.
 
29) Aozasa K, Takakuwa T, Nakatsuka S:Pyothorax-associated lymphoma;A lymphoma developing in chronic inflammation. Adv Anat Pathol 2:324-331, 2005.
PubMed

[4] 悪性リンパ腫と染色体や遺伝子の異常

P.36 掲載の参考文献
1) 木村暢宏:リンパ球の遺伝子再構成とsomatic hypermutation. 血液・腫瘍科49:31-37, 2004,
 
2) Storb U:The molecular basis of somatic hypermutation of immunoglobulin genes. Curr Opin Immunol 8:206-214, 1996.
PubMed
3) 三浦偉久男:悪性リンパ腫の染色体異常;染色体異常を解釈するために. 医学のあゆみ12:960-963, 2005,
 
4) Motokura T, Bloom T, et al:A novel cyclin encorded by a bcl1-linked candidate oncogene Nature 350:512-515, 1991.
 
5) 三浦偉久男:診断技術の進歩;その意義;染色体分析. 臨牀検査51:389-393, 2007,
 
6) Weinberg RA:The retinoblastoma protein and cell cycle control. Cell 81:323-330, 1995.
PubMed
7) Cieary ML, Sklar J:Nucleotide sequence of a t (14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster rejoin near a transcriptionally active locus on chromosome 18, Proc Natl Acad Sci USA 82:7439-7444, 1985.
 
8) Tilly H, Rossi A, Stamatoullas A, et al:Prognostic values of chromosomal abnormalities in follicular lymphoma. Blood 84:1043-1049, 1994.
PubMed
9) Offit K, Parsa NZ, Gaidano G et al:6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma. Blood 82:2157-2162, 1993.
PubMed
10) Elenitoba-Johnson KS, Gascoyne RD, Lim MS, et al:Homozygous deletions at chromosome 9p12 involving p16 and p15 are associated with histologic progression in follicule center lymphoma. Blood 91:4677-4685, 1998.
 
11) Even Gl, Wyllie AH, et al:Induction of apoptosis in fibroblasts by c-myc protein. Cell 69:119, 1992.
 
12) Kramer MH, Hermans J, et al:Clinical relevance of BCL2, BCL6, and MYC rearrangement in diffuse large B-cell lymphoma, Blood 92:3152, 1998.
 
13) Yano T, Sander CA, Clark HM, et al:Clustered mutation in the second exon of the MYC gene in sporadic Burkitt's lymphoma, Oncogene 8:2741-2748, 1993,
PubMed
14) 黒川峰夫:転写因子, 血液・腫瘍科49:54-60, 2004.
 
15) Ueda C, Uchiyama T, Ohno H, etal:Immunogiobulin (Ig) /BCL6 versus non-Ig/BCL6 gene fusion in diffuse large-B cell lymphoma corresponds to a high-versus low-level expression of BCL6 mRNA. Blood 99:2624-2625, 2002.
PubMed
16) Tamaru J, Hummel M, et al:Burkitt's lymphoma express VH genes with a moderate number of antigen-selected somatic mutations. Am J Pathol 147:1398-1407, 1995.
PubMed
17) Ott G, Katzenberger T, Greiner A, et al:The t (11;18) (q21:q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin's lymphomas of the mucosa-associated lymphoid tissue (MALT-) type, Cancer Res 57:3944-3648, 1997.
 
18) Yonezumi M, Suzuki R, Suzuki H, et al:Detection of API2-MALTI chimaeric gene in extra nodal marginal zone B-cell lymphoma by reverse transcription polymerase chain reaction (PCR) and genomic long and accurate PCR analysis. Br J Haematol 115:588-594, 2001.
 
19) Touriol C, Greenland C, et al:Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma;2cases expressing ALK kinase fused to CLTCL. Blood 95:3204-3207, 2000.
 
20) Lamant L, Dastugue N, et al:A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1:2) (q25;p23) translocation. Blood 93:3088-3095, 1999,
PubMed
21) Hernadez L Pinyol M, et al:TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood 94:3265-3268, 1999,
 

[5] 悪性リンパ腫の診断に必要な検査、病期診断、治療効果判定法

P.52 掲載の参考文献
1) The International Non-Hodgkin's Lymphoma Prognostic Factors Project:A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993.
 
2) Jaffe ES, Harris NL, Stein H, et al:World Health Organization Classification of Tumors. Pathology and genetics of tumors of Haematopoietic and lymphoid tissue. IARC press, Lyon, 2001,
 
3) 日本臨床検査協議会血液検査標準化検討委員会フローサイトメトリーワーキンググループ:フローサイトメトリーによる造血器腫瘍細胞表面抗原検査に関するガイドライン (JCCLS H2-P V1,0). 日本臨床検査標準協議会会誌18 (2):69-107, 2003,
 
4) Stelzer GT, Shults KE, Loken MR:CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Ann NY Acad Sci 677:265-280, 1993.
PubMed
5) Carbone PP, Kaplan HS, Musshoff K, et al:Report of the committee on Hodgkin's disease staging classification. Cancer Res 31:1860-1861, 1971.
 
6) AJCC cancer staging manual. 6th ed, pp393-403, Springer, New York, 2002,
 
7) Tsukamoto N, Kojima M, Hasegawa M, et al:The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and a comparison of 18F-FDG-PET with 67Gallium scintigra-phy in the evaluation of lymphoma;Relation to histologic subtypes based on the World Health Organization classification. Cancer 110:652-659, 2007.
 
8) Isasi CR, Lu P, Blaufox MD, et al:A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 104:1066-1074, 2005.
PubMed
9) Cheson B, Pfistner B, Juweid ME, et al:Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007.
PubMed
10) Cheson BD, Horning SJ, Coiffier B, et al:Report of an International Workshop to standardize response criteria for Non-Hodgkin's lymphomas. J Clin Oncol 7:1244-1253, 1999.
 
11) Therasse P, Arbuck SG, Eisenhauer EA, et al:New guidelines to evaluate the response to treatment in solid tumors, J Natl Cancer Invest 92:205-21 6, 2000.
 

[6] 悪性リンパ腫治療に使用される薬物

P.64 掲載の参考文献
1) 上田孝典:化学療法. 三輪血液病学, 第3版, 浅野茂隆,池田康夫,内山卓 (監), pp 609-663, 文光堂, 東京, 20053
 
2) Schornagel JH, McVie JG:The clinical pharmacology of methotrexate. Cancer Treat Rev 10:53-75, 1983.
PubMed
3) Treon SP, Chabner BA:Concepts in use of high-dose methotrexate therapy. Clin Chem 42:1322-1329, 1996.
PubMed
4) Tobinai K, Watanabe T, Ogura M, et al:Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma. J Clin Oncol 24:174-180, 2006.
PubMed
5) Gandhi V, Plunkett W:Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 41:93-103, 2002.
PubMed
6) Kawasaki H, Carrera CJ, Piro LD, et al:Relationship of deoxycytidine kinase and cytoplasmic 5:-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 81:597-601, 1993.
 
7) Kufe DW, Major PP, Egan EM, et al:Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem 255:8997-9000, 1980.
 
8) Kishi S, Goto N, Nakamura T, et al:Evaluation of cell-kiliing effects of 1-beta-D-arabinofuranosyl-cytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system. Cancer Res 59:2629-2634, 1999.
 
9) DeAngelo DJ, Yu D, Johnson JL, et al:Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma;Cancer and Leukemia Group B study 19801.Blood 109:5136-5142, 2007.
 
10) Gewirtz DA:A critical evaluation of the mechanisms of action proposed forthe antitumoreffects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727-741, 1999.
 
11) Shan K, Lincoff AM, Young JB:Anthracycline-induced cardiotoxicity. Ann Intern Med 125:47-58, 1996.
PubMed
12) Ishisaka T, Kishi S, Okura K, et al:A precise pharmacodynamic study showing the advantage of a marked reduction in cardiotoxicity in continuous infusion of doxorubicin. Leuk Lymphoma 47:1599-1607, 2006.
PubMed
13) Shenkenberg TD, Von Hoff DD:Mitoxantrone;anew anticancer drug with significant clinical activity. Ann Intern Med 105:67-81, 1986.
 
14) Tew O, Coivine R, Chabner A:Alkylating Agents. Cancerchemotherapy and biotherapy-Principles and practice, 3rd ed, Chabner B, Longo D (eds), pp 373-414, Lippincott Willians and Wilkins, Philadelphia, 2001.
 
15) Reed E:Cisplatin. Cancer Chemother Biol Response Modif 18:144-151, 1999.
PubMed
16) Clark Pl, Slevin ML:The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 12:223-252, 1987.
 
17) Mathijssen RH, Loos WJ, Verweij J, et al:Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets 2:103-123, 2002.
PubMed
18) Toffoli G, Cecchin E, Corona G, et al:The role of UGTIA1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24:3061-3068, 2006.
 
19) Boye J, Elter T, Engert A:An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 14:520-535, 2003.
PubMed
20) Tobinai K:Proteasome inhibitor, bortezomib, for myeloma and lymphoma. Int J Clin Oncol 12:318-326, 2007.
PubMed

[7] 悪性リンパ腫の放射線治療

P.77 掲載の参考文献
1) Perez CA, Brady LW, Halperin EC, et al (eds):Principle and Practice of Radiation Oncology. Lippincott Williams&Wilkins, Philadelphia, 2004.
 
2) Leibel SA, Phillips TL (eds):Textbook of Radiation Oncology. Saunders, Philadeiphia, 2004.
 
3) Specht L, Gray RG, Clarke MJ, et al:Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease;ameta-analysis of 23 randomized trials involving 3, 888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 16:830-843, 1998.
 
4) Mac Manus MP, Hoppe RT, et al:Is radiotherapy curative for stage I and II low grade follicularlymphoma?Results of long Term follow up of patients Treated at Stanford University. J Clin Oncol 14:1282, 1996
 
5) Ha CS, Kong JS, Tucker SL, et al:Centralymphatic irradiation for stage I-III follicular lymphoma;report from a single-institutional prospective study. Int J Radiat Oncol Biol Phys 57:316-320, 2003.
 
6) Tsang RW, Gospodarowicz MK, Pintilie M, et al:Stage I and II MALT lymphoma;results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys 50:1258-1264, 2001.
 
7) Schleicher NR, Portlock CS, Yahalom J:Treatment of mucosa-associated lymphoid Tissue lymphoma of the stomach with radiation alone. J Clin Oncol 16:1916-1921, 1998.
 
8) Liebross RH, Ha CS, Cox JD, et al:Solitary bone plasmacytoma;outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Bioi Phys 41:1063-1067, 1998.
 
9) Miller TP, Dahlberg S, Cassady JR, et al:Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma N Eng J Med 339:21-26, 1998.
 
10) Horning SJ, Weiler E, Kim K, et al:Chemotherapy with or without radiotherapy in limited stage diffuse aggressive non-Hodgkin's lymphoma;Eastern Cooperative Oncology Group study 1484.J Clin Oncol 22:3032-3038, 2004.
 
11) Bonnet C, et al:CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients;a study by the Gronpe d:Etude des lymphomes de l' Adulte. J Clin Oncol 25:757-759, 2007.
 
12) Rosenbluth BD, Yahalom J:Highly effective local control and palliation of Mantle cell lymphoma with involved-field radiation therapy. Int J Radiat Oncol Biol Phys 65:1185-1191, 2006.
PubMed
13) Cheung MMC, et al:Early stage nasal NK/T-cell lymphoma:clinical outcome, prognostic factor, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 54:182-190, 2002.
PubMed
14) Isobe K, Uno T, Tamaru J, et al:Extranodal Natural Killer/T-cell lymphoma, nasal type;the significance of radiotherapeutic parameters. Cancer 106:609-61 5, 2006.
PubMed
15) Siegel RS, Pandolfino T, GuiTarT J, et al:Primary cutaneous T-cell lymphoma;review and current concepts. J Clin Oncol 18:2908-2925, 2000.
PubMed
16) Haas RL, Poortmans P, de Jong D, et al:Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients. Eur J Cancer 41:1724-1730, 2005.
PubMed
17) Kahn ST, Flowers C, Lechowicz MJ, et al:Value of PET restaging after chemotherapy for non-Hodgkin's lymphoma;Implications for consolidation radiotherapy. Int J Radiat Oncol Biol Phys 66:961-965, 2006.
PubMed
18) 小口正彦:ホジキンリンパ腫の放射線治療血液フロンティア (特集:ホジキンリンパ腫;最近の進歩) 14:51-56, 2004,
 
19) Girinsky T, van der Maazen R, Specht L, et al:Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma;concepts and guidelines. Radiother Oncol 79:270-277, 2006.
PubMed
20) Nasir S, DeAngelis LM:Update on The management of primary CNS lymphoma. Oncology 14:228-234, 2000.
PubMed

[8] 悪性リンパ腫の予後因子と治療選択

P.90 掲載の参考文献
1) Jaffe ES, Harris NL Stein H, et al (eds):World Health Organization classification of tumors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues, IARC Press, Lyon, 2001.
 
2) The International Non-Hodgkin's Lymphoma Prognostic Factors Project:A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993.
 
3) Solal-Celigny P, Roy P, Colombat P, et al:Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004.
PubMed
4) Hasenclever D, Diehl V:A prognostic score for advanced Hodgkin's disease;International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998.
 
5) Coiffier B, Brousse N, Peuchmaur M, et al:Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas;a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen;The GELA (Groupe d:Etude des Lymphomes Agressives) . Ann Oncol 1:45-50, 1990.
 
6) Melnyk A, Rodriguez A, Pugh WC, et al:Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 89:4514-4520, 1997.
PubMed
7) Shiota M, Nakamura S, Ichinohasama R, etal:Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK;a distinct clinicopathologic entity, Blood 86:1954-1960, 1995.
PubMed
8) The Non-Hodgkin's Lymphoma Classification Project:A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's Lymphoma. Blood 89:3909-3918, 1997.
 
9) Gisselbrecht C, Gaulard P, Lepage E, et al:Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas;Groupe d'Etudes des Lymphomes de l'Adulte (GELA) . Blood 92:76-82, 1998.
 
10) Kinoshita T, Hotta T, Tobinai K, et al:A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate-or high-grade non-Hodgkin's lymphoma:Japan Clinical Oncology Group Study 9002.Int J Hematol 80:341-350, 2004.
PubMed
11) Kinoshita T, Hotta T, Shibata T, et al:Peripheral T-Cell Lymphoma-Unspecified (PTCL-U) and NK/T-Cell Lymphoma Showed a Significantly Poor Prognosis in a Randomized Controlled Trial (RCT) JCOG9002 with Multidrug Combination Chemotherapy for Aggressive Lymphoma. Blood 108:698a (abstract#2465), 2006.
 
12) Gallamini A, Stelitano C, Calvi R, et al:Peripheral T-cell lymphoma unspecified (PTCL-U);a new prognostic model from a retrospective multicentric clinical study. Blood 103:2474-2479, 2004.
 
13) Coiffier B, Lepage E, Briere J, et al:CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma N Engl J Med 346:235-242, 2002.
PubMed
14) Sehn LH, Berry B, Chhanabhai M, et al:The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857-1861, 2007.
 
15) Rosenwald A, Wright G, Chan WC, et al:The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. N Engl J Med 346:1937-1947, 2002.
PubMed
16) Hans CP, Weisenburger DD, Greiner TC, et al:Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004.
PubMed
17) Nyman H, Adde M, Karjalainen-Lindsberg ML, et al:Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 109:4930-4935, 2007.
PubMed
18) Hermine O, Haioun C, Lepage E, et al:Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma;Groupe d:Etude des Lymphomes de l'Adulte (GELA) . Blood 87:265-272, 1996.
 
19) Hill ME, MacLennan KA, Cunningham DC, et al:Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma;a British National Lymphoma Investigation Study. Blood 88:1046-1051, 1996.
PubMed
20) Mounier N, Briere J, Gisselbrecht C, et al:Rituximab plus CHOP (R-CHOP) overcomes bcl-2;associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL) . Blood 101:4279-4284, 2003.
 
21) Lossos IS, Jones CD, Warnke R, et al:Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 98:945-951, 2001.
PubMed
22) Winter JN, Weller EA, Horning SJ, et al:Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP;a prospective correlative study. Blood 107:4207-4213, 2006.
PubMed
23) Ichikawa A, Kinoshita T, Watanabe T, et al:Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337:529-534, 1997.
PubMed
24) Hiraga J, Kinoshita T, Ohno T, et al:Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma Int J Hematol 84:248-255, 2006.
PubMed
25) Farinha P, Sehn L, Skinnider B, et al:Strong p53 Expression Is an Independent Predictor of Outcome in De Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Either CHOP or CHOP-R. Blood 108:244a, 2006.
 
26) Shipp MA, Abeloff MD, Antman KH, et al:International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas;report of the jury. J Clin Oncol 17:423-429, 1999.
 
27) Gianni AM, Bregni M, Siena S, et al:High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma N Engl J Med 336:1290-1298, 1997.
PubMed
28) Milpied N, Deconinck E, Gaillard F, et al:Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350:1287-1295, 2004.
PubMed
29) Martelli M, Vignetti M, Zinzani PL et al:High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy;aprospective randomizeditalian multicenter study. J Clin Oncol 14:534-542, 1996,
 
30) Gisselbrecht C, Lepage E, Mojina T, et al:Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 20:2472-2479, 2002.
PubMed
31) Miller TP, Dahlberg S, Cassady JR, et al:Chemotherapy Alone Compared with Chemotherapy plus Radiotherapy for Localized Intermediate-and High-Grade Non-Hodgkin's Lymphoma. N Engl J Med 339:21-26, 1998.
PubMed
32) Reyes F, Lepage E, Ganem G, et al:ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 352:1197-1205, 2005.
PubMed
33) Bonnet C, Fillet G, Mounier N, et al:CHOP Alone Compared With CHOP Plus Radiotherapy for Localized Aggressive Lymphoma in Elderly Patients;A Study by the Groupe d:Etude des Lymphomes de l'Adulte. J Clin Oncol 25:787-792, 2007.
 
34) Cheson BD, Pfistner B, Juweid ME, et al:Revised Response Criteria for Malignant Lymphoma. J Clin Oncol 25:579-586, 2007.
PubMed
35) Hutchings M, Loft A, Hansen M, et al:FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52-59, 2006.
PubMed
36) Kostakoglu L, Goldsmith SJ, Leonard JP, et al:FDG-PET after 1 cycle of therapy predicts outcomein diffuse large cell lymphoma an:d classic Hodgkin disease. Cancer 107:2678-2687, 2006.
 

[9] JCOGリンパ腫グループによる多施設共同臨床試験

P.98 掲載の参考文献
1) Lymphoma Study Group. Combination chemotherapy wlth vincristine, cyclophosphamide (Endoxan), prednisolone and adriamycin (VEPA) in adult non-Hodgkin's lymphoid malignancies;relation between T-cell of non-T-cell phenotype. Jpn J Clin Oncol 9:397-406, 1979.
 
2) Lymphoma Study Group:Final results of cooperative study of VEPA[vincrisitine, cyclophospha-mide (Endoxan), prednisolone and adriamycin]therapy in advanced adult non-Hodgkin's lymphoma:relation between T-or B-cell phenotype and response. Jpn J Clin Oncol 12:227-238, 1982.
 
3) 下山正徳,田島絹子, 恒松隆一郎, ほか:厚生省がん助成金指定研究「固形がんの集学的治療の研究」 班における臨床試験計画 (プロトコール) の作成と実施, 並びに結果の統計解析とその評価に関するガイドライン (改訂第3版);第I部プロトコールの作成に関する医学的並びに科学的事項とその審査. 癌の臨床42:197-229, 1996,
 
4) 下山正徳, 江口研二, 恒松隆一郎, ほか:厚生省がん助成金指定研究「固形がんの集学的治療の研究」 班における臨床試験計画 (プロトコール) の作成と実施並びに結果の統計解析とその評価に関するガイドライン(改訂第3版);第II部がん臨床試験のインフォームド・コンセントの指針. 癌の臨床 42:339-352, 1996.
 
5) Takenaka T, Mikuni C, Sasaki T, et al:Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage H-IV Hodgkin's disease;a multicenter phase II study (8905) Jpn J Clin Oncol 30:146-152, 2000.
 
6) Ogura M, Takenaka T, Kagami Y, et al:Phase II study od ABVd therapy for advanced Hodgkin's disease (HD) in Japan;Japan Clinical Oncology Group (JCOG) study (JCOG9305) . Proc Am Soc Clin Oncol 20:230b, 2001 (Abstract#2673) .
 
7) Ogura M, Morishima Y, Itoh K, et al:Dacarbazine (DTIC) can not be deleted from ABVD therapy for advanced Hodgkin's lymphoma (HL):Japan Clinical Oncology Group (JCOG) study (JCOG9305) . Proc Am Soc Clin Oncol 22:573, 2003 (Abstract#2303) .
PubMed
8) Fukuhara S, Shimoyama M, Minato K, et al:Interim analysis of LSG-4 protocol study on the treatment of aggressive non-Hodgkin:lymphoma in Japan. Cancer Chemotherapy;Challenge for the future 10.8, pp289-294, Elsevier Science, New York, 1993.
 
9) Kinoshita T, Hotta T, Tobinai K, et al:A randomized controlled trial investigatingthe survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate-or high-grade non-Hodgkin's lymphoma;Japan C]inical Oncoiogy Group study 9002.Int J Hematol 80:341-350, 2004.
 
10) Mizoroki F, Hirose Y, Sano M, et al:A phase II study of VEPA/FEPP chemotherapy for aggressive lymphoma in elderiy patients;Japan Clinical Oncology Group study JCOG9203.Int J Hematol 83:55-62, 2006.
 
11) Itoh K, Ohtsu T, Fukuda H, et al:Randomized Phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma:Japan Clinical Oncology Groupstudy 9505.Ann Oncol 13:1347-1355, 2002.
 
12) 小椋美知則, 竹山邦彦 ,木下朝博ほか:高risk群, 初発進行期aggressive NHLへのauto-HSCT併用大量化学療法の多施設共同第II相試験 (JCOG9506) . 臨床血液46:732, 2005 (Abstract#WS-1-2) .
 
13) Ogura M, Kagami Y, Itoh K, et al:Standard CHOP therapy for low (L) or low-intermediate (L-1) risk patients (pts) with aggressive non-Hodgkin's lymphoma (NHL);A multicenter phase II study by Japan Clinical oncology Group (JCOG9508) . Proc Am Soc Clin Ocncol 23:606, 2004 (Abstract #6703) .
 
14) Hotta T, Shimakura Y, Ishizuka N, et al:Randomized phase III study of atandard CHOP (S-CHOP) versus biweekly CHOP (Bi-CHOP) in aggressive non-Hodgkin's lymphoma (NHL);Japan Clinical Oncology Group study, JCOG9809.Proc Am Sco Clin Oncol 22:565, 2003 (Abstract#2271) .
 
15) 飛内賢正, 山口素子, 小口正彦, ほか:限局期鼻NK/T細胞リンパ腫に対する放射線治療とDeVIC療法同時併用の第I/II相試験 (JCOG0211-Dl);第I相の結果.第68回日本血液学会総会・第48回日本臨床血液学会合同総会, ワークショップ18, 福岡, 2006,
 
16) Kobayashi T, Tobinai k, Shimoyama M, et al:Long-term follow-up results of adult patients with acute lymphocytic leukemia or lymphoblastic lymphoma treated with short-term, alternating non-cross-resistant chemotherapy:Japan Clinical Oncology Group study 8702.Jpn J Clin Oncol 29:340-348, 1999.
PubMed
17) Tobinai K, Takeyama K, Arima F, et al:Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphobiastic lymphoma;Japan Clinical Oncology Group study 9004.Cancer Sci 98:1350-1357, 2007.
PubMed
18) Tsukasaki K, Tobinai K, Shimoyama M, et al:Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma;Japan Clinical Oncoiogy Group study (JCOG9109) . Int J Hematol 77:164-170, 2003.
 
19) Yamada Y, Tomonaga M, Fukuda H, et al:A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukemia-lymphoma;Japan Clinical Oncology Group study 9303.Br J Hematol 113:375-382, 2001.
 
20) Tsukasaki K, Utsunomiya A, Fukuda H, et al:VCAP-AMP-VECP versus biweekly CHOP for adult T-cell leukemia-lymphoma;Japan Clinical Oncology Group Study, JCOG9801.J Clin Oncol 25:5458-5464, 2007.
 
21) Takenaka T, Shirakawa S, Mukuni C, et al:Alternating combination chemotherapy COP (cyclophosphamide, vincristine, prednisone) and MP (melphalan, prednisone) in multiple myeloma;a multicenter phase II study (JCOG8906) . Jpn J Clin Oncol 29:485-489, 1999.
 
22) Takenaka T, Itoh K, Suzuki T, et al:Phase III study of ranimustine, cyclophasphamide, vincristine, melpharan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma;A Japan Clinical Oncol Group study, JCOG 93011 Int J Hematol 79:165-173, 2004.
 

[10] 臨床試験とインフォームド・コンセント

P.108 掲載の参考文献
1) 星野一正:医療の倫理岩波書店, 東京, 1991.
 
2) 柳田邦男:元気の出るインフォームドコンセント. 中央法規出版, 東京, 1996.
 
3) 日本医師会 (訳):ヘルシンキ宣言 (ヒトを対象とする医学研究の倫理的原則). 2000.
 
4) Simon RM: Design and anafiysis of clinical trials. Cancer, Principles and Practice of Oncology, 7th ed, DeVita VT Jr., Hellman S, Rosenberg SA (eds), pp471-505, Lippincott Williams&Wilkins (LWW), Philadelphia, 2005.
 
5) 日本臨床腫瘍学会: 新臨床腫瘍学, がん薬物療法専門医のために 南江堂, 東京, 2006.
 

[11] ホジキンリンパ腫の治療

P.118 掲載の参考文献
1) Diehl V, Sextro M, Franklin J, et al:Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease;Report from the European Task Force on Lymphoma project on lymphocyte-predominant Hodgkin's disease. J Clin Oncol 17:776-783, 1999.
PubMed
2) Lister TA, Crowther D, Sutcliffe SD, et al:Report of a committee to discuss the evaluation and staging of the patients with Hodgkin's disease;Cotswolds meeting. J Clin Oncol 7:1630-1636, 1989.
 
3) Mauch PM:Controversies in management of early stage Hodgkin's disease. Blood 83:318-329, 1994.
PubMed
4) Hasenclever D, Diehl V:A prognostic score for advanced Hodgkin's disease;International Prognostic Factors Project on advanced Hodgkin's disease. N Engl J Med 339:1506-1514, 1998.
 
5) Carde P, Burgers M, Henry-Amar M, et al:Clinical stage I and II Hodgkin's disease;A specifically tailored therapy according to prognostic factors;1977-1982 H5 controlled trails program. J Clin Oncol 6:239-252, 1988.
 
6) Horning S, Hoppe RT, Mason J, et al:Stanford-Kaiser Permanente GI study for clinical stage I and II A Hodgkin's disease;Subtotal lymphoid irradiation versus vinblastine, methotrexate anbleomycin chemotherapy and regional irradiation. J Clin Oncol 15:1736-1744, 1997.
 
7) Noordijk EM, Carde P, Dupouy N, et al:Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma;long-term results of the European Organization for Research and Treatment of Cancer H7 randomized controlled trials:J Clin Oncol 24:3128-31 35, 2006.
 
8) Bonadonna G, Bonfante V, Viviani S, et al:ABVD plus subtotal versus invo) ved-field radiotherapy in early-stage Hodgkin's disease;long-term results. J Clin Oncol 22:2835-2841, 2004.
 
9) Meyer RM, Gospodarowicz MK, Connoers JM, et al:Randamized Comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's Lymphoma;National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23:4634-4642, 2005.
 
10) Canellos GP, Anderson JR, Cella DF, et al:Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992.
PubMed
11) Diehl Y, Franklin J, Pfreundschuh M, et al:Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003.
 
12) Yuen AR, Rosenberg SA, Hoppe RT, et al:Comparison Between Conventional Salvage Therapy and High-Dose Therapy With Autografting for Recurrent or Refractory Hodgkin's Disease. Blood 89:814-822, 1997.
PubMed
13) Schmitz N, Pfistner B, Sextro M, et al:Aggressive conventional chemotherapy compared with highdose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease;a radomized trial. Lancet 359:2065-2071, 2002.
 
14) Peggs K, Hunter A, Chopra R, et al:Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogenic transplantation. Lancet 365:1934-1941, 2005.
PubMed

[12] 濾胞性リンパ腫の治療

P.132 掲載の参考文献
1) Rosenberg SA:Karnofsky memorial lecture. The low-grade non-Hodgkin's lymphoma;challenges and opportunities. J Clin Oncol 3:299-310, 1985.
PubMed
2) Apostolidis J, Gupta RK, Grenzelias D, et al:High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma;long-term clinical and molecular follow-up. J Clin Oncol 18:527-536, 2000.
PubMed
3) Mac Manus MP, Hoppe RT:Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14:1282-1290, 1996.
 
4) Horning SJ, Rosenberg SA:The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311:1471-1475, 1984.
PubMed
5) Hiddemann W, Kneba M, Dreyling M, et al:Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicuiar flymphoma compared with therapy with CHOP alone;results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005.
 
6) Marcus R, Imrie K, Belch A, et al:CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005.
PubMed
7) Dana BW, Dahlberg S, Nathwani BN, et al:Long-term follow-up patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11:644-651, 1993.
PubMed
8) Czuczman MS, Weaver R, Alkuzweny B, et al:Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy;9-year follow-up. J Clin Oncol 22:4711-4716, 2004.
PubMed
9) Czuczman MS, Grillo-Lopez AJ, White CA, et al:Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276, 1999.
PubMed
10) Solal-Celigny P, Roy P, Colombat P, et al:Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004.
PubMed
11) Kaminski MS, Tuck M, Estes J, et al:1311-Tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441-449, 2005.
 
12) Gordon Li, Molina A, Witzig T, et al:Durable responses after ibritumomab tiuxetan radioimmuno-therapy for CD20+ B-cell lymphoma;long-term follow-up of a phase 1/2 study. Blood 103:4429-4431, 2004.
 
13) Bennett JM, ark Kaminski S, Leonard JP, et al:Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 105:4576-4582, 2005.
 
14) Press OW, Unger JM, Braziel RM, et al:Phase II trial of CHOP chemotherapy followed by tositumomab/iodine l-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma;Five-year follow-up of Southwest Oncology Group Protocol S9911.J Clin Oncol 24:4143-4149, 2006.
 
15) Leonard JP, Coleman M, Kostakoglu L, etal:Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine 1131 tositumomab for untreated follicular lymphoma. J Clin Oncol 23:5696-5704, 2005.
 
16) Sebban C, Mounier N, Brousse N, et al:Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma;the GELF-94 randomized study from the Groupe d:Etude des Lymphomes de l'Adulte (GELA) . Blood 108:2540-2544, 2006.
 
17) Deconinck E, Foussard C, Milpied N, et al:High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma;a radomized multicenter study by GOELAMS. Blood 105:3817-3823, 2005.
 
18) Lenz G, Dreyling M, Schiegnitz E, et al:Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma;results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104:2667-2674, 2004.
 
19) van Besien K, Loberiza FR Jr, Bajorunaite R, et al:Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102:3521-3529, 2003.
PubMed
20) Khouri IF, Saliba RM, Giralt SA, et al:Nonablative allogenic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma;low incidence of toxicity, acute graft-versus-host disease, and treatment-related morta[ity. Blood 98:3595-3599, 2001.
 

[13] MALTリンパ腫の治療

P.141 掲載の参考文献
1) Isaacson P:Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) . IRAC Press, Lyon, 2001.
 
2) Thieblemont C, Berger F, Dumonlet C, et al:Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 95:802-806, 2000.
 
3) Harris NL, Jaffe ES, Diebold J, et al:World Health Organization Classification of neoplastic diseases of the hematopoietic and lymphoid tissues;Report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997.Journal of Clinical Oncology 17:3835-3849, 1999.
PubMed
4) Willis TG, Jadayel DM, Du M-Q, et al:Bcl 10 is involved in t (1;14) (p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 96:35-45, 1999.
 
5) Ott G, Katzenberger T, Greiner A, et al:The t (11;18) (q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but, not high-grade malignant non-Hodgkin's lymphoma of the mucosa-associated lymphoid tissue (MALT-) type. Cancer Research 57:3944-3948, 1997.
 
6) Dierlamm J, Baens M, Wlodarska l, et al:The apoptosis inhibitor gene AP12 and a novel 18q gene, MLT, are recurrently rearranged in the t (11;18) (q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 93:3601-3609, 1999.
 
7) Kobayashi Y, Nakata M, Maekawa M, et al:Detection of t (11;18) in MALT-type lymphoma with dual-color fluorescence in sitor hybridization and reverse transcriptase-polymerase chain reaction analysis. Diagn Mol Pathol 10:207-213, 2001.
 
8) Remstein ED, James CD, Kurtin PJ:Incidence and subtype specificity of API-MALTI fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. American Journal of Pathology 156:1183-1188, 2000.
 
9) Baens M, Maes B, Steyls A, et al:The Product of the t (11;18), an AP12-MLT fusion, marks nearly half og gastric MALT type lymphomas without large cell proliferation. American Journal of Hematology 156:1433-1439, 2000.
 
10) Starostik P, Patzner J, Greiner A, et al:Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct pathogenetic pathways. Blood 99:3-9, 2002.
 
11) Wotherspoon AC, Finn TM, Isaacson PG:Trisomy 3 in low-grade B-cell lymphomas of mucosa-associated lymphoid tissue. Blood 85:2000-2004, 1995.
PubMed
12) Hoeve MA, Ferreira Mota SC, Schuuring E, et al:Frequent allelic imbalance but infrequent microsatellite instability in gastric lymphoma Leukemia 13:1804-1811, 1999.
PubMed
13) Dierlamm J, Wlodarska I, Michaux L, et al:Genetic abnormalities in marginal zone B-cell lymphoma. Hematol Oncol 18:1-13, 2000,
PubMed
14) Streubel B, Lamprecht A, dierlamm j, et al:t (14;18) (q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 101:2335-2339, 2003.
PubMed
15) Streubel B, Vinatzer U, Lamprecht A, et al:T (3;14) (p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 19:652-658, 2005.
 
16) Tanimoto K, Sekiguchi N, Yokota Y, et al:Fluorescence in situ hybridization (FISH) analysis of primary ocular adnexal MALT lymphoma. BMC Cancer 6:249, 2006.
PubMed
17) 小田一郎, 齊藤大三, 小野裕之, ほか:胃MALTリンパ腫のHelicobacter pylori除菌後の経過と治療効果;主に臨床の立場から. 胃と腸34:1381-1388, 1999,
 
18) Alpen B, Neubauer A, Dierlamm J, et al:Translocation t (11;18) absent in early gastric marginal zone B-cell lymphoma of MALT type responding to erradication of Helicobacter pylori infection. Blood 15:4014-4015, 2000.
 
19) Sano T, Sasako M, Kinoshita T, et al:Total gastrectomy for primary gastric lymphoma at stage I E and II E;aprospective study of fifty cases. Surgery 121:501-505, 1997.
 
20) Schechter NR, Portlock CS, Yahalom J:Treatement of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. JCO 16:1916-1921, 1998.
 
21) Koch P, Valle Fd, Berdel WE, et al:Priamry gastrointestinal non-Hodgkin's lymphoma;II. Combined surgical and conservative or conservative management only on localized gastric lymphoma-results of the prospective German multicenter study GIT NHL 01/92.JCO 19:3874-3883, 2001.
 
22) 大津敦:消化管悪性リンパ腫に対する非外科的治療の適応と有効性の評価に関する研究. 平成10年厚生労働省がん研究助成金による報告書, pp425-456, 1998.
 
23) Inagaki H, Chan JK, Ng JW, et al:Primary thymic extranodal marginal-zone B-cell lymphoma of mucosa-associated lymphoid tissue type exhibits distinctive clinicopathological and molecular features, Am J Pathol 160:1435-1443, 2002.
PubMed
24) Nakata M, Katsumata N, Takenaka T, et al:Histology according to the Revised European American Lymphoma classification significantly predicts the prognosis of ocular adnexal lymphoma. Leukemia Lymphoma 32:533-543, 1999.
 
25) Tanimoto K, Kaneko A, Suzuki S, et al:Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. Ann Oncol 17:135-140, 2006.
PubMed
26) Majoney D, Grillo-L6pez A, White C, et al:IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195, 1997.
 
27) Jager G, Neumeister P, Brezinschek R, et al:Treatement of extranodal marginal zone B-cell lymphoma od mucosa-associated lymphoid tossue type with cladribine;A Phase II study. JCO 20:3872-3877, 2002.
 
28) Witzig TE, Gordon L, Emmnouilides C, et al:Safety and efficacy of Zevalin in four patients with mucosa associated lymphoid tissue (MALT) lymphoma. Blood 98:254b, 2001
 

[14] マントル細胞リンパ腫の治療

P.163 掲載の参考文献
1) Banks P, et al:Mantle cell lymphoma;A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 16:637-640, 1992.
PubMed
2) Fisher RI, Dahlberg S, Nathwani BN, et al:A clinical analysis of two indolent lymphoma entities;mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories);a Southwest Oncology Group study. Blood 85:1075-1082, 1995.
 
3) Teodorovic I, Pittaluga S, Kluin-Nelemans JC, et al:Efficacy of four different regimens in 64 mantle-cell lymphoma cases;clinicopathologic comparison with 498 0ther non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment Of Cancer Lymphoma Cooperative Group. J Clin Oncol 13:2819-2826, 1995.
 
4) The Non-Hodgkin's Lymphoma Classification Project:A clinical evaluation of the Internationai Lymphoma Study Group classification of non-Hodgkin's lymphoma Blood 89:3909-3918, 1997.
 
5) Yatabe Y, et al:Significance of cyclin DI overexpression for the diagnosis of mantie cell Lymphoma;aclinicopathologic comparison of cyclin D1-positive MCL and cyclin DI-negative MCL-like B-cell lymphoma Blood 95:2253-2261, 2000.
 
6) Hoster E, Dreyling M, Klapper W, et al:A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111:558-565, 2008.
PubMed
7) Coiffier B, Haioun C, Ketterer N, et al:Rituximab (anti-CD20 monoclonal antibody) for tetreatment of patients with relapsing or refractory aggressive lymphoma;a multicenter phase II study. Blood 92:1927-1932, 1998.
PubMed
8) Foran JM, et al:Phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma J Clin Oncol 18:317-324, 2000.
 
9) Czuczman MS, Grillo-Lopez AJ, White CA, et al:Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276, 1999.
PubMed
10) Coiffier B, Lepage E, Briere J, et al:CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346:235-242, 2002.
PubMed
11) Howard OM, Gribben JG, Neuberg DS, et al:Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma;Molecular Complete Responses Are Not Predictive of Progression-Free Survival. J Clin Oncol 20:1288-1294, 2002.
PubMed
12) Lenz G, Dreyling M, Hoster E, et al:Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma;results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) . J Clin Oncol 23 (9):1984-1992, 2005.
PubMed
13) Khouri IF, Romaguera J, Kantarjian H, et al:Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation;an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16:3803-3809, 1998.
PubMed
14) Voso MT, et al:In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/ mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 109 (4):729-735, 2000.
PubMed
15) Magni M, Di Nicola M, Devizzi et al:Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma;Evidence for a role of both chemotherapy and rituximab infusion. Blood 96:864-869, 2000.
PubMed
16) Ogura M, Kagami Y, Taji H, et al:Phase I/H Study of New Salvage Therapy (CHASE) for Refractory or Relapsed Malignant Lymphomas. Int J Hematol 77:503-511, 2003.
PubMed
17) Oki Y, Ogura M, Kato H:Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma Cancer Sci 99:179-184, 2008.
PubMed
18) Romaguera JE, Fayad L, Rodriguez MA, et al:High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23:7013-7023, 2005.
PubMed
19) Ghielmini M, Schmitz SF, Cogliatti S, et al:Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma;astudy of the Swiss Group for Clinical Cancer Research (SAKK) . J Clin Oncol 23 (4):705-711, 2005.
PubMed
20) Forstpointner R, Unterhalt M, Dreyling M, et al:Maintenance therapy with rituximab leads to a significant proiongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas:Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG) . Blood 108:4003-4008, 2006.
 
21) Witzig TE, Gordon Ll, Cabanillas F, et al:Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non+lodgkin:s lymphoma. J Clin Oncol 20:2453-2463, 2002.
 
22) Younes A, Pro B, Rodriquez MA, et al:Activity of Yttrium 90 (90Y) lbritumomab Tiuxetan (Zevalin(R)) in 22 Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL) . Blood 106 (11):Abstract 2452, 2005.
 
23) Press OW, Eary JF, Appelbaum FR, et al:Radio-labeled-antibody therapy of B-cell lymphoma with autologous bone marrow support N Engl J Med 329:1219-1224, 1993.
 
24) Behr TM, Griesinger F, Riggert J, et al:High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support;Results of a pilot study. Cancer 94 (4 Suppl):1363-1372, 2002.
 
25) Gopai AK, Rajendran JG, Petersdorf SH, et al:High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle ceil lymphoma. Blood 99:3158-3162, 2002.
 
26) Siavin S, Nagler A, Naparstek E, et al:Nonmyeloablative stem cell transplantation and celltherapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756-763, 1998.
 
27) Khouri IF, Keating M, Korbling M, et al:Transplant-lite;induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16:281 7-2824, 1998.
 
28) Khouri IF, Lee MS, Saliba RM, et al:Nonablative Allogeneic Stem-Cell Transplantation for Advanced/Recurrent Mantle-Cell Lymphoma. JCO 2003:4407-4412, 2003,
 
29) Tobinai K, Watanabe T, Ogura M, et al:Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma. J Clin Oncol 24:174-180, 2006.
PubMed
30) Decaudin D, Bosq J, Tertian G, et al:Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol 16:579-583, 1998.
PubMed
31) Foran JM, Rohatiner AZ, Coiffier B, et al:Multicenter Phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 17:546-553, 1999.
PubMed
32) Zinzani PL, Magagnoli M, Moretti L, et al:Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol 18:773-779, 2000.
PubMed
33) Forstpointner R, Dreyling M, Repp R, et al:The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refra cto ry follicular and mantle cell lymphomas;results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104:3064-3071, 2004.
 
34) Rummel MJ, Al-Batran SE, Kim SZ, et al:Bendamustine plus rituximab is effective and has a favorable toxicity profile inthe treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 23:3383-3389, 2005.
 
35) O'Connor OA, Wright J, Moskowitz C, et al:Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantlecell lymphoma. J Clin Oncol 23 (4):676-684, 2005.
PubMed
36) Read MA, Neish AS, Luscinskas FW, et al:The proteasome pathway is required for cytokineinduced endothelial-leukocyte adhesion molecule expression. Immunity 2 (5):493-506, 1995.
PubMed
37) Fisher RI, Bernstein SH, Kahl BS, et al:Multicenter phase II study of bortezomib in patients with relapsed or refractory Mantle cell lymphoma, J Clin Oncol 24:4867-4874, 2006.
 
38) Hay N, Sonenberg N:Upstream and downstream of mTOR. Genes Dev 18:1926-1945, 2004.
PubMed
39) Bjornsti MA, Houghton PJ:The TOR pathway:A target for cancertherapy. Nat Rev Cancer 4:335-348, 2004.
 
40) Dancey JE:Clinical development of mammaiian target of rapamycin inhibitors. Hematol Oncol Clin North Am 16:1101-1114, 2002.
 
41) Mita MM, Mita A, Rowinsky EK:Mammalian target of rapamycin;A new molecular target for breast cancer. Clin Breast Cancer 4:126-137, 2003.
PubMed
42) Witzig TE, Geyer SM, Ghobrial I, et al:Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23 (23):5347-5356, 2005.
PubMed

[15] 中悪性度リンパ腫の治療

P.180 掲載の参考文献
1) Hiddemann W, Longo DL, Coiffier B, et al:Lymphoma classification;the gap between biology an clinical management is closing. Blood 88:4085-4089, 1996.
PubMed
2) Lymphoma Study Group of Japanese Pathologists:The world health organization classification o malignant lymphomas in japan;incidence of recently recognized entities. Pathol Int 50:696-702 2000.
 
3) The International Non-Hodgkin's Lymphoma Prognostic Factors Project:A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993.
 
4) Sehn LH, Berry B, Chhanabhai M, et al:The revised International Prognostic Index (R-IPI) is better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphom treated with R-CHOP. Blood 109:1857-1861, 2007.
 
5) Miller TP, Dahlberg S, Cassady JR, et al:Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma N Engl J Me 339:21-26, 1998.
 
6) Horning SJ, Weller E, Kim K, et al:Chemotherapy with or without radiotherapy in limited-stag diffuse aggressive non-Hodgkin's lymphoma;Eastern Cooperative Oncology Group study 1484.Clin Oncol 22:3032-3038, 2004,
PubMed
7) Reyes F, Lepage E, Ganem G, et al:ACVBP versus CHOP pius radiotherapy for localized aggressive lymphoma N Engl J Med 352:1197-1205, 2005
 
8) Bonnet C, Fillet G, Mounier N, et al:CHOP alone compared with CHOP plus radiotherapy fo localized aggressive lymphoma in elderly patients;astudy by the Groupe d:Etude des Lymphome de l'Adulte. J Clin Oncol 25:787-792, 2007.
 
9) Fisher Rl, Gaynor ER, Dahlberg S, et al:Comparison of a standard regimen (CHOP) with thre intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328 1002-1006, 1993.
 
10) Coiffier B, Lepage E, Briere J, et al:CHOP chemotherapy plus rituximab compared with CHO alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346:235-242, 2002.
 
11) Pfreundschuh M, Trumper L, Osterborg A, et al:CHOP-like chemotherapy plus rituximab versus 180 CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:a randomised controlled trial by the MabThera International Trial (MInt) Group. Lancet Oncol 7:379-391, 2006.
 
12) Habermann TM, Weller EA, Morrison VA, et al:Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006.
PubMed
13) Lepage E, Gisselbrecht C, Haioun C, et al:Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients;application to LNH-87 protocol;The GELA (Groupe d:Etude des Lymphomes de l'Adulte) . Ann Oncol 4:651-656, 1993.
 
14) Lyman GH, Dale DC, Friedberg J, et al:Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma:anationwide study. J Clin Oncol 22:4302-4311, 2004,
 
15) Smith TJ, Khatcheressian J, Lyman GH, et al:2006 update of recommendations for the use of white blood cell growth factors;an evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205, 2006,
PubMed
16) Haioun C, Lepage E, Gisselbrecht C, et al:Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma;updated results of the prospective study LNH87-2;Groupe d:Etude des Lymphomes de l'Adulte. J Clin Oncol 15:1131-1137, 1997.
 
17) Gisselbrecht C, Lepage E, Molina T, et al:Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 20:2472-2479, 2002.
PubMed
18) Martelli M, Gherlinzoni F, De Renzo A, et al:Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma:an Italian multicenter randomized trial. J Clin Oncol 21:1255-1262, 2003,
 
19) Milpied N, Deconinck E, Gaillard F, et al:Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350:1287-1295, 2004.
PubMed
20) Tirelli U, Errante D, Van Glabbeke M, et al CHOP is the standard regimen in patients >or=70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma;results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 16:27-34, 1998.
PubMed
21) Tilly H, Lepage E, Coiffier B, et al:Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102:4284-4289, 2003.
PubMed
22) Pfreundschuh M, Trumper L, Kloess M, et al:Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas;results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641, 2004.
 
23) Philip T, Guglielmi C, Hagenbeek A, et al:Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995.
PubMed
24) Kewalramani T, Zelenetz AD, Nimer SD, et al:Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103:3684-3688, 2004.
PubMed

[16] 高悪性度リンパ腫(前駆Tリンパ芽球性リンパ腫とバーキットリンパ腫)の治療

P.198 掲載の参考文献
1) Jaffe ES, Harris NL Stein H, et al (eds):World Health Organization Classification of Tumors;Pathology and Genetics;Tumor of Hematopoietic and Lymphoid Tissues. IARC press, Lyon, 2001.
 
2) The non-Hodgkin's lymphoma classlficatlon project:A clinical evaluation of the International lymphoma study group. Blood 11:3909-3918, 1997.
 
3) Lymphoma study group of Japanese pathologist:The World Health Organizatlon classification of malignant lymphomas in Japan:Incidence of recently recognized entities. Pathol Int 50:696-702, 2000.
 
4) 岡本昌隆:活動状況・各種統計. 悪性リンパ腫・臨床と病理:ALTSGの研究から, 平野正美 (編), pp14-28, 先端医学社, 東京, 2005.
 
5) Brunning RD, Flandrin G, Borwitz M, et al:Precursor T lymphoblastic leukemia/lymphoma (Precursor T-cell acute lymphoblastic leukemia) . World Health Organization Classification of Tumors;Pathology and Genetics;Tumor of Hematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, et al (eds), pp115-117, IARC press, Lyon, 2001.
 
6) 神野正敏:リンパ芽球白血病/リンパ腫. 悪性リンパ腫・臨床と病理;ALTSGの研究から, 平野正美 (編), pp146-150, 先端医学社, 東京, 2005.
 
7) Brunning RD, Flandrin G, Borwitz M, et al Precursor T lymphoblastic leukemia/lymphoma (Precursor B-cell acute lymphoblastic leukemia) . Worid Health Organization Classification of Tumors;Pathology and Genetics;Tumor of Hematopoietic and Lymphoid Tissues, Jafe ES, Harris NL, Stein H, et al (eds), pp111-114, IARC press, Lyon, 2001.3
 
8) Kaneko Y, Frizzera G, Shikano T, et al:Chromosomal and immunophenotypic patterns in T cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LBL) . Leukemia 3:886-892, 1989.
 
9) Kaneko Y, Frizzera G, Maseki N, et al:A novel translocation, t (9;17) (q34;q23), in aggressive childhood lymphoblastic lymphoma. Leukemia 2:745-748, 1988.
PubMed
10) Thomas DA, Kantarjian HM:Lymphoblastic lymphoma. Hematol Oncol North Am 15:51-95, 2001.
 
11) Anderson JR, Jenkin DT, Wilson JF, et al:Long-term follow up of patients treated with COMPor LSA2L2 therapy for childhood non-Hodgkin lymphoma;A report of CCG-551 from the children cancer group. J Clin Oncol 11:1024-1032, 1993.
 
12) Reiter A, Schrapper M, Ludwig WD, et al:Intensive ALL-type therapy without local radiotherapy provided a 90%event-free survival for children with T-cell lymphoblastic lymphoma:a BFM group report. Blood 95:416-421, 2000.
 
13) Hoelzer D, Gokbuget N, Digel W, et al:Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 99:4379-4385, 2002.
 
14) Thomas DA, O'Brien S, Cortes J, et al:Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 104:1624-1630, 2004.
PubMed
15) Dabaja BS, Ha CS, Thomas DA, et al:The role of local radiation therapy for mediastinal disease in aduits with T-cell lymphoblastic lymphoma. Cancer 94:2738-2744, 2002.
 
16) Millot F, Suciu S, Philippe N, et al:Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia;Result of the European Organization for Research and Treatment of Cancer 58881 randomized Phase III trial. J Clin Oncol 19:1935-1942, 2001.
 
17) Sweetenham JW, Liberti G, Pearce R, et al:High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma;results of European Group for Bone Marrow Transplantation. J Clin Oncol 12:1358-1365, 1994.
 
18) Sweetenham Jw, Santini G, Qian W, et al:High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma;Results of a randomized trial of the European Groupfor Bbod and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 19:2927-2936, 2001.
 
19) Bouabdallah L, Xerri L, Bardou VJ, et al:Role of induction chemotherapy and bone marrow transplantation in adultl ymphoblastic lymphoma:A report on 62 patients from single center. Ann Oncol 9:619-625, 1998.
 
20) Chopra R, Goldstone AH, Pearce R, et al:Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma:Acase-controlled analysis of the European Bone Marrow Transplant Group registry data. J Clin Oncol 10:1690-1695, 1992.
 
21) Levine JE, Harris RE, Loberiza FR, et al:A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 101:2476-2482, 2003.
PubMed
22) Deangelo D, Yu D, Dodge RK, et al:Phase II study of 2-amino-9-b-D-arabinosyl-6-methoxy-9Hpurine (506∪78) in patients with relapsed or refractory T-lineage acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL):CALGB study 19801.Blood 100:198a, 2002.
 
23) Kantarjian H, Gandhi V, Cortes J, et al:Phase II clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 102:2379-2386, 2003.
 
24) 中村直哉:バーキットリンパ腫/白血病. 最新・悪性リンパ腫アトラス, 菊池昌弘, 森 茂郎 (編), pp190-196, 文光堂, 東京, 2004.
 
25) Blum KA, Lozanski G, Byrd C:Adult Burkitt leukemia and lymphoma. Blood 104:3009-3020, 2004.
 
26) Murphy SB:Classification, staging and end resuits of childhood non-Hodgkin lymphomas;Dissimilarities from lymphomas in adults. Semin Oncol 7:332-339, 1980.
 
27) Diebold J, Jaffe ES, Raphael M, et al:Burkitt. World Health Organization Classification of Tumors:Pathology and Genetics;Tumor of Hematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, et al (eds), pp115-117, IARC press, Lyon, 2001L
 
28) Bociek RG:Adult Buukitt:s lymphoma. Clin Lymphoma 6:11-20, 2005.
PubMed
29) Divine M, Lepage E, Briere J, et al:Is the smali non-cleaved-cell lymphoma histologic subtype a poor prognostic factor inadult patients?A case-controlled analysis. J Clin Oncol 14:240-248, 1996.
 
30) Magrath I, Adde M, Shad A, et al:Adults and children with small non-cleaved-cell lymphma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14:925-934, 1996.
 
31) Mead GN, Sydes MR, Walewski J, et al:An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma;results of United Kingdom Lymphoma Group LYO6 study. Ann Oncol 13:1264-1274, 2002.
 
32) Thomas DA, Cortes J, O'Brien S, et al:Hyper-CVAD program in Burkitt's type adult acute lymphoblastic lymphoma J Clin Oncol 17:2461-2470, 1999,
 
33) Lee E, Petroni G, Schiffer C, et al:Brief-duration high-intensity chemotherapy for patients with small non-cleaved cell lymphoma or FAB L3 acute lymphocytic leukemia;results of Cancer and Leukemia Group B study 9251.J Clin Oncol 19:4014-4022, 2001.
PubMed
34) Thomas DA, Faderl S, O'Brien S, et al:Chemoimmunotherapy with hyper-CVAD plus rituxumab for the treatment of adult Burkitt and Burkitt type lymphoma or acute lymphoblastic leukemia. Cancer 106:1569-1580, 2006.
PubMed
35) Sweetenham JW, Pearce R, Taghipour G, et al:Adult Burkitt's and Burkitt's like non-Hodgkin's lymphoma;Outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first relapse or relapse;Results from the European Group for Blood and Marrow Transplantation. J Clin Oncol 14:2465-2472, 1996.
 
36) Sweetenham JW, Proctor SJ, Blaise D, et al:High-dose therapy and autologous bone marrow transplantation in first complete remission for adult patients with high-grade non-Hodgkin's lymphoma;the EBMT experience. Ann Oncol 5 (suppl 2):155-159, 1994.
 
37) Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al:An EBMT registry matched study of al ogeneic stem cell transplants for lymphoma;aliogeneic transplantation is associated with a lower relapse rate but higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31:667-678, 2003.
 
38) Cortes J, Thomas D, Rios A, et al:Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 94:1492-1499, 2002.
PubMed
39) Kaplan LD, Lee JY, Ambinder RF, et al:Rituximab does not improve clinical outcome in randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non Hodgkin's lymphoma;AIDS-Malignancies Consortium Trial 010. Blood 106:1538-1543, 2005.
 

[17] 末梢性T細胞リンパ腫とNK/T細胞リンパ腫の治療

P.212 掲載の参考文献
1) Fisher Rl, Gaynor ER, Dahlberg S, et al:Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma N Engl J Med 328:1002-1006, 1993.
 
2) Gisselbrecht C, Gaulard P, Lepage E, et al:Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas;Groupe d:Etudes des Lymphomes de l'Adulte (GELA) . Blood 92:76-82, 1998.
 
3) The Non-Hodgkin's Lymphoma Classification Project:A clinical evaluation of the International Lymphoma Study Group ciassification of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997.
 
4) Mori M, Kitamura K, Masuda M, et al:Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COPversus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma. Int J Hematol 81:246-254, 2005.
PubMed
5) Kim SW, Tanimoto TE, Hirabayashi N, et al:Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma;anationwide survey in Japan. Blood 108:382-389, 2006.
 
6) Gallamini A, Zaja F, Patti C, et al:Alemtuzumab (Campath-1H) and CHOP chemotherapy as firstline treatment of peripheral T-cell lymphoma;results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110:2316-2323, 2007.
PubMed
7) Lee J, Suh C, Park YH, et al:Extranodal natural killer T-cell lymphoma nasal-type;aprognostic model from a retrospective multicenter study. J Clin Oncol 24:612-618, 2006.
 
8) Kim WS, Song Sy, Ahn YC, et al:CHOP followed by involved field radiation;is it optimal for Iocalized nasal natural killer/T-cell lymphoma?Ann Oncol 12:349-352, 2001.
 
9) Lee SH, Ahn YC, Kim WS, et al:The effect of pre-irradiation dose intense CHOP on anthracycline resistance in localized nasal NK/T-cell lymphoma. Haematologica 91:427-428, 2006 (letter) ,
PubMed
10) Li YX, Yao B, Jin J, et al:Radiotherapy as primary treatment for stage I E and II E nasal natural killer/T-cell lymphoma. J Clin Oncol 24:181-189, 2006.
 
11) Kim K, Chie EK, Kim CW, et al:Treatment outcome of angiocentric T-cell and NK/T-cell lymphoma, nasal type;radiotherapy versus chemotherapy. Jpn J Clin Oncol 35:1-5, 2005.
PubMed
12) Lee KW, Yun T, Kim DW, et al:First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapt+/-radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. Leuk Lymphoma 47:1274-1282, 2006.
 
13) Koom WS, Koom WS, Chung EJ, et al:Angiocentric T-cell and NK/T-cell lymphomas;radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys 59:1127-1137, 2004.
PubMed
15) Cheung MM, Chan JK, Lau WH, et al:Early stage nasal NK/T-cell lymphoma;clinical outcome, prognostic factor, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 54:182-190, 2002.
PubMed
16) Isobe K, Uno T, Tamaru J, et al:Extranodal natural killer/T-cell lymphoma, nasal type;the significance of radiotherapeutic parameters, Cancer 106:609-615, 2006.
PubMed
17) Yamaguchi M, Ogawa S, Nomoto Y, et al:Treatment outcome of nasal NK-cell lymphoma;A report of 12consecutively-diagnosed cases and a review of the literature. J Clin Exp Hematop 41:93-99, 2001.
 
18) Au WY, Lie AK, Liang R, et al:Autologous stem celltransplantation fornasal NK/T-cell lymphoma;aprogress report on its vaiue. Ann Oncol 14:1673-1676, 2003.
 
19) Kim HJ, Bang SM, Lee J, et al:High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma;a retrospective comparison with non-transplantation cases. Bone Marrow Transplant 37:819-824, 2006.
PubMed
20) Aviles A, Neri N, Fernandez R, et al:Nasal NK/T-cell lymphoma with disseminated disease treated with aggressive combined therapy. Med Oncol 20:13-17, 2003.
PubMed
21) Yong W, Zheng W, Zhang Y, et al:L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol 78:163-1 67, 2003.
 
22) Murashige N, Kami M, Kishi Y, et al:Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural kilfier-cell neoplasms. Br J Haematol 130:561-567, 2005.
PubMed
23) Suzuki R, Suzuki R, Suzumiya J, et al:Hematopoietic stem cell transplantation for natural kille-cell lineage neoplasms. Bone Marrow Transplant 37:425-431, 2006,
 
24) Yamaguchi M, et al:Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK) /T-cell lymphoma and leukemia, Cancer Sci 99:1016-1020, 2008.
PubMed
14|) Shikama N, lkeda H, Nakamura S, et al:Localized aggressive non-Hodgkin's lymphoma of the nasal cavity:a survey by the Japan Lymphoma Radiation Therapy Group. Int J Radiat Oncol Biol Phys 51:1228-1233, 2001.
 

[18] 成人T細胞白血病/リンパ腫の治療

P.226 掲載の参考文献
1) Takatsuki K (ed):Adult T-cell Leukemia. Oxford University Press, New York, 1994.
 
2) IARC Working Group on the Evaluation of Carcinogenic Risks to Humans:Human immunodeficiency viruses and human T-cell lymphotropic viruses. IARC Monographs on the evaluation of carcinogenic risks to humans, IARC Press, Lyon, 1996.
 
3) Kikuchi M, et al:Adult T-cell leukaemia/lymphoma. WHO Classification of Tumours;Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, et al (eds), pp200-203, IARC Press, Lyon, 2001.
 
4) Lymphoma Study Group (1984-1987):Major prognostic factors of patients with adult T-cell Leukemia-lymphoma;a cooperative study. Leuk Res 15:81, 1991.
 
5) 塚崎邦弘:成人T細胞白血病/リンパ腫 (ATLL) の治療の進歩, Annual Review血液2007, pp170-182, 中外医学社, 東京, 2007.
 
6) Shimoyama M:Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma;A report from the Lymphoma Study Group (1984-87) . Br J Haematol 79:428, 1991.
 
7) Shimoyama M:Chemotherapy of ATL. Adult T-cell Leukemia, Takatsuki K (ed), p221, Oxford University Press, New York, 1994.
 
8) Tsukasaki K, Tobinai K, Shimoyama M, et al:Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma:Japan Clinical Oncology Group Study (JCOG9109) . Int J Hematol 77:164, 2003
 
9) Yamada Y, Tomonaga M, Fukuda H, et al:A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukemia-lymphoma;Japan Clinical Oncology Group Study 9303.Br J Haematol 113:375, 2001.
 
10) Tsukasaki K, Utsunomiya A, Fukuda H, et al:VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma;Japan Clinical Oncology Group Study JCOG9801.J Clin Oncol 25 (34):5458-5456, 2007
 
11) 朝長万左男, ほか:抗がん剤適正使用ガイドライン作成ワーキンググループ抗がん剤適正使用のガイドライン;造血器腫瘍. International Journal of Clinical Oncology 10 (Suppl):1-14, 2005[臨床血 液46 (11):1233-1247, 2005に転載],
 
12) 高崎由美, 塚崎邦弘, 岩永正子, ほか:Indolent type成人T細胞白血病/リンパ腫 (ATLL) の長期予後の解析. 日本臨床血液学会誌49:283 (抄録), 2007.
 
13) Taguchi H, Kinoshita KI, Takatsuki K, et al:An intensive chemotherapy of adult T-cell leukemia/lymphoma;CHOP followed by etoposide, vindesine, ranimustine, and mitxantrone with granulocyte colony-stimulating factor support. J Acquir Immune Defic Syndr Hum Retroviol 12:182, 1996.
 
14) Uozumi K, Hanada S, Ohno N, et al:Combination chemotherapy (RCM protocol:response-oriented cyclic multidrug protocol) for the acute or lymphoma type adult T-cell leukemia. Leuk Lymphoma 18:31 7, 1995.
PubMed
15) Utsunomiya A, Miyazaki Y, Takatsuka Y, et al:Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 27 (1):15-20, 2001.
PubMed
16) Kami M, Hamaki T, Miyakoshi S, et al:Allogeneic haematopoietic stem cell transplantation forthe treatment of adult T-cell leukaemia/lymphoma. Br J Haematol 120 (2):304-309, 2003.
 
17) Okamura J, Utsunomiya A, Tanosaki R, et al:Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood 105:4143, 2005.
PubMed
18) Fukushima T, Miyazakl Y, Honda S, et al:Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia 5:829, 2005.
 
19) Nakase K, Hara M, Kozuka T, et al:Bone marrow transplantation from unrelated donors for patients with adult T-cell leukaemia/lymphoma. Bone Marrow Transplant 37 (1):41-44, 2006.
PubMed
20) Kato K, et al:Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virusu-1-negative donors for adult T-cell leukaemia/lymphoma;retrospective analysis of data from the Japanese Marrow Donor Program. Biol Bone Marrow Transplant 13 (1):90-99, 2007.
 
21) Gill PS, Harrington W Jr, Kaplan MH, et al:Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alpha and zidovudine. New Engl J Med 332:1744-1748, 1995.
PubMed
22) Tobinai K, Kobayashi Y, Shimoyama M:Interferon alpha and zidovudine in adult T-cell leukemia-lymphoma;Lymphoma Study Group of the Japan Clinical Oncology Group. N Engl J Med 333:1285, 1995.
 
23) Watanabe T, Yamaguchi K, Takatsuki K, et al:Constitutive expression of parathyroid hormone-related protein gene in human T cell leukemia virus type 1 (HTLV-1) carriers and adult T cell leukemia patients that can be trans-activated by HTLV-1 tax gene. J Exp Med 172 (3):759-765, 1990.
PubMed
24) Nosaka K, Miyamoto T, Sakai T, et al:Mechanism of hypercalcemia in adult T-cell leukemia;overexpression of receptoractivator of nuclear factor kappaB ligand on adult T-cell fleukemia cells. Blood 99 (2):634-640, 2002:
 
25) Hino S:Primary Prevention of Adult T Cell Leukemia (ATL) in Nagasaki, Japan by Refraining from Breast feeding. Two Decades of Adult T-Cell Leukemia and HTLV-1 Research, Sugamura K, et al (eds), PP241-252, Japan Scientific Societies Press, Tokyo, 2003.
 
26) 武本重毅, 塚崎邦弘, 田口博國, ほか:成人T細胞白血病リンパ腫 (ATL) における微少残存病変 (MRD) 検査法の臨床応用についての研究. 日本臨床血液学会誌46:774 (抄録), 2005.
 

[19] 高齢者悪性リンパ腫の治療

P.239 掲載の参考文献
1) The Non-Hodgkin's Lymphoma Classification Project:Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. Ann Oncol 8:973-978, 1997.
PubMed
2) Charlson ME, Pompei P, Ales KL, et al:A new method of classifying prognostic comorbidity in longitudinal studies;development and validation. J Chronic Dis 40:373-383, 1987.
PubMed
3) van Spronsen DJ, Janssen-Heijnen ML, Breed WP, et al:Prevalence of comorbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkins lymphoma, 1993-1996.Ann Hematol 78:315-31 9, 1999.
 
4) Mori M, Niitsu N, Takagi T, et al:Reduced-dose chop therapy for elderly patients with non-Hodgkin's lymphoma leuk Lymphoma 41:359-366, 2001.
PubMed
5) Niitsu N, Iijima K:Full-dose CHOP chemotherapy combined with granulocyte coiony-stimulating factor for aggressive non-Hodgkin's lymphoma in elderly patients;a prospective study. Ann Hematol 80:602-606, 2001.
PubMed
6) Pfreundschuh M, Trumper L, Kloess M, et al;German High-Grade Non-Hodgkin's Lymphoma Study Group:Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas;results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641, 2004.
 
7) Mori M, Kitamura K, Masuda M, et al:Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma Int J Hematol 81:246-254, 2005.
PubMed
8) Niitsu N, Umeda M:Response and adverse drug reactions to combination chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma;comparison of CHOP, COP-BLAM, COP-BLAM III, and THP-COPBLM. Eur J Haematol 63:337-344, 1999.
PubMed
9) Sonneveld P, de Ridder M, van der Lelie H, et al:Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 13:2530-2539, 1995.
PubMed
10) Zinzani PL, Gherlinzoni F, Storti S, et al:Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients. Ann Oncol 13:1364-1369, 2002.
PubMed
11) Tilly H, Lepage E, Coiffier B, et al;Groupe d:Etude des Lymphomes de l'Adulte:Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma Biood 102:4284-4289, 2003.
 
12) Niitsu N, Okamoto M, Kohori M, et al:Multicenter Phase H study of CyclOBEAP regimen for elderly patients with poor-prognosis aggressive lymphoma Hematol Oncol 24:220-206, 2006.
 
13) Coiffier B, Lepage E, Briere J, et al:CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346:235-242, 2002.
PubMed
14) Feugier P, Van Hoof A, Sebban C, et al:Long-term results of the R-CHOPstudy inthe treatment of elderly patients with diffuse large B-cell lymphoma;a study by the Groupe d:Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126, 2005.
 
15) Mounier N, Briere J, Gisselbrecht C, et al:Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma. Haematologica 91:715-716, 2006.
PubMed
16) Winter JN, Weller EA, Horning SJ, et al:Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP;a prospective correiative study. Blood 107:4207-4213, 2006.
PubMed
17) Miller TP, Dahlberg S, Cassady JR, et al:Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med 339:21-26, 1998
PubMed
18) Bonnet C, Fillet G, Mounier N, et al:CHOP a[one compared with CHOP plus radiotherapy for Iocalized aggressive lymphoma in elderly patients:A study by the Groupe d:Etude des Lymphomes de l'Adulte. J Clin Oncol 25:787-792, 2007.
 
19) Miller TP, Unger JM, Spier C, et al:Effect of adding rituximab to three cycles of CHOP plus involved-fieid radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG-0014) . Blood 104:158a, 2004.
 

[20] 小児悪性リンパ腫の治療

P.252 掲載の参考文献
1) Jaffe ES, Harris NL, Stein H, et al:World Health Organization Classification of Tumours "Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues". IARC press, Lyon, 2001.
 
2) Murphy SB:Classification, staging and results of treatment of childhood NHL, dissimilarities from lymphoma in adults. Seminars in Oncology 7:332, 1980.
 
3) Reiter A, Schrappe M, Tiemann M, et al:Improved treatment results in childhood B-cell neopiasms with tailored intensification of therapy;a reports of the Berlin-Frankfurt-Munster Group trial NHL-BFM 90.Blood 94:3294, 1999.
 
4) Patte C, Auperin A, Michon J, et al:The Societe Frangaise d:Oncologie Pediatrique LMB89 protocol;highly effective multiagent chemotherapy tailored to the tumor burden and response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97:3370, 2001.
 
5) Patte C, Auperin A, Gerrard M, et al:Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents;it is possible to reduce treatment for the early responding patients. Blood 109:2773, 2007.
 
6) Jeha S, Kantarjian H, lrwin D, et al:Efficacy and safety of rasburicase, a recombinant urate oxidse, in the management of malignancy-associated hyperuricemia in pediatric and adult patients:final results of a multicenter compassionate use trial. Leukemia 19:34-38, 2005.
 
7) Reiter A, Schrappe M, Ludwig WD, et al:Intensive ALL-type therapy without bcal radiotherapy provides a 90%event-free survival for children with T-cell lymphoblastic lymphoma;a BFM Group report. Blood 95:416, 2000.
 
8) Le Deley MC, Reiter A, Williams D, et al:Prognostic factors in childhood anaplastic large cell lymphoma (ALCL):results of the European intergroup study (abstract) . Ann Oncol 10:28, 1999.
 
9) Seidemann K, Tiemann M, Schrappe M, et al:Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma;a report of the Berlin-Frankfurt-Munster Group trial NHL-BFM 90.Blood 97:3699, 2001.
PubMed
10) Lister TA, Crowther D, Sutcliffe SB, et al:Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease;Cotswolds meeting. J Clin Oncol 7:1630, 1989.
PubMed
11) Nachman JB, Sposto R, Herzog P, et al:Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 20:3765, 2002.
PubMed
12) Schellong G, Potter R, Bramswig J, et al:High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease;the German-Austrian multicenter trial DAL-HD-90, The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 17:3736, 1999.
 
13) 熊谷昌明, 瀧本哲也, 三間屋純一, ほか:本邦の小児ホジキンリンパ腫155例の後方視的検討;4小児がん研究グループによるアンケート調査結果. 臨床血液44:146, 2003
 

[21] 消化管に発生するリンパ腫の治療

P.260 掲載の参考文献
1) Koch P, del Valle F, Berdel WE, et al;German Multicenter Study Group:Primary gastrointestinal non-Hodgkins lymphoma:II. J Clin Oncol 19 (18):3874-3883, 2001.
 
2) Rohatiner A, d:Amore F, Coiffier B, et al Report on a workshop convened to discuss report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol (5):397-400, 1994.
PubMed
3) Hatano B, Ohshima K, Tsuchiya T, et al:Clinicopathological features of gastric B-cell lymphoma;a series of 317cases. Pathol Int 52 (11):677-682, 2002,
PubMed
4) 中村常哉:悪性リンパ腫 (佐野分類/「胃と腸」胃悪性リンパ腫編集小委員会の分類) . 内視鏡診断のプロセスと疾患別内視鏡像, 長南明道ほか (編),, 日本メディカルセンター東京, 2007.
 
5) Jaffe ES, et al (eds):World Health Organization classification of tumors, Pathology and Genetics of Tumours of Haematopoietic and lymphoid of Tissues. IARC Press, Lyon, 2001.
 
6) Miller TP, Dahlberg S, Cassady JR, et al:Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med 339 (1):21-26, 1998.
PubMed
7) Ishikura S, Tobinai K, Ohtsu A, et al:Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II, diffuse large B-cell lymphoma of the stomach. Cancer Sci 96 (6):349-352, 2005.
 
8) Ferreri AJ, Montalban C:Primary diffuse large B-cell lymphoma of the stomach. Crit Rev Oncol Hematol 63 (1):65-71, 2007.
PubMed
9) Asaka M, Kimura T, Kudo M, et al:Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 102 (3):760-766, 1992.
 
10) Wotherspoon AC, Doglioni C, Diss TC, et al:Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342 (8871):575-577, 1993.
PubMed
11) Nakamura T, Inagaki H, Seto M, et al:Gastric low-grade B-cell MALT lymphoma;treatment, response, and genetic alteration. J Gastroenterol 38 (10):921-929, 2003.
PubMed
12) Inagaki H, Nakamura T, Li C, et al:Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter Pylori eradication and detection of AP12-MALTI fusion. Am J Surg Pathol 28 (12):1560-1567, 2004.
 
13) Schechter NR, Portlock CS, Yahalom J:Treatment of mucosa-associated lymphoid tissuelymphoma of the stomach with radiation alone. J Clin Oncol 16 (5):1916-1921, 1998,
 
14) Tsang RW, Gospodarowicz MK, Pintilie M, et al:stage I and II MALT lymphoma;results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys 50 (5):1258-1264, 2001.
 
15) Yoshino T, Miyake K, Ichimura K, et al:Increased incidence of follicular lymphoma in the duodenum. Am J Surg Pathol 24 (5):688-693, 2000.
PubMed
16) Zettl A, deLeeuw R, Haralambieva E, et al:Enteropathy-type T-cell lymphoma. Am J Clin Pathol 127 (5):701-706, 2007.
PubMed
17) Chott A, Dragosics B, Radaszkiewicz T:Peripheral T-cell lymphomas of the intestine. Am J Pathol 141 (6):1361-1371, 1992,
PubMed
18) Wong MT, Eu KW. Primary colorectal lymphomas. Colorectal Dis 8 (7). 586-591, 2006,
PubMed
19) Cho MJ, Ha CS, Allen PK, et al:Primary non-Hodgkin lymphoma of the large bowel. Radiology 205 (2):535-539, 1997.
PubMed
20) Kodama T, Ohshima K, Nomura K, et al:Lymphomatous polyposis of the gastrointestinal tract, including mantle cell lymphoma, follicular lymphoma and mucosa-associated lymphoid tissue lymphoma. Histopathology 47 (5):467-478, 2005
PubMed

[22] 脳に発生するリンパ腫の治療

P.274 掲載の参考文献
1) Olson JE, Janney CA, Rao RD et al:The continuing increase in the incidence of primary CNS non-Hodgkin flymphoma. Cancer 95 (7):1504-1510, 2002.
 
2) Bessell EM, Hoang-Xuan K, Ferreri AJ, et al:Primary central nervous system lymphoma;biological aspects and controversies in management. Eur J Cancer 43:1141-1152, 2007.
PubMed
3) Raval SN, Yahalom J, DeAngelis LM:Management of central nervous system lymphoma, Non-Hodgkin's lymphomas, Mauch PM, Armitage JO, Coiffier B, et al (eds), pp 643-655, Lippincott Williams & Wilkins, Philadelphia, 2004.
 
4) Aozasa K, Ohsawa M, Ya mabe H, et al:Malignant lymphoma of the central nervous system in Japan. Int J Cancer 45:632-636, 1990.
 
5) Shibata T, Suzumiya J, Tamura K, et al:Primary central nervous system lymphoma. Internal Medicine 41:283-289, 2002,
PubMed
6) Ferreri AJM, Blay JY, Reni M, et al:Prognostic scoring system for primary CNS lymphomas;the international extranodal lymphoma study group experience. J Clin Oncol 21:266-272, 2003.
 
7) 薄井紀子:まれな節外性リンパ腫;中枢神経, 骨, 生殖器, 医学のあゆみ212 (5):491-498, 2005.
 
8) Ferreri AJ, Reni M, Pasini F, et al:A multicenter study of treatment of primary CNS lymphoma. Neurology 58:1513-1520, 2002.
PubMed
9) Rubenstein JL, Fridlyand J, Shen A, et al:Gene expression and angiotropism in primary CNS lymphoma, Blood 107:3716-3723, 2006.
PubMed
10) Abrey LE, Batchelor TT, Ferreri AJM, et al:report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034-5043, 2005.
PubMed
11) Ferreri AJ, Abrey LE, Blay JY, et al:Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12to 15, 2002.J Clin Oncol 21:2407-2414, 2003.
 
12) Deangelis LM, lwamoto FM:An update on therapy of primary central nervous system lymphoma. Hematology Am Soc Hematol Educ Program, pp 311-316, 2006 (http://asheducationbook.hemato-logylibrary.org/cgi/reprint/2006/1/311) .
 
13) Skarin AT, Zuckerman KS, Pitman SW, et al:High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin's lymphoma including CNS involvement. Blood 50:1039-1047, 1977.
PubMed
14) Abrey LE, Yahalaom J, DeAngelis LM:Treatment for primary CNS lymphoma;The next step. J Clin Oncol 18:3144-3150, 2000.
PubMed
15) Hiraga S, Arita N, Ohnishi T, et al:Rapid infusion of high-dose methotrexate resulting in enhaned penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas, J Neurosurg 91:221-230, 1999.
 
16) Doolittle ND, Miner ME, Hall WA, et al:Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatmentof patients with malignant brain tumors. Cancer 88:637-647, 2000.
 
17) Fliessbach K, Helmstaedter C, Urbach H, et al:Neuropsychological outcome after chemotherapy for primary CNS lymphoma;aprospective study. Neurology 64:1184-1188, 2005.
 
18) Illerhaus G, Marks R, lhorst G, et al:High-Dose Chemotherapy With Autologous Stem-Cell Transplantation and Hyperfractionated Radiotherapy As First-Line Treatment of Primary CNS Lymphoma J Clin Oncol 24:3865-3870, 2006.
 
19) Levine AM, Said JW:Management of acquired immunodeficiency syndrome-related lymphoma. Non-Hodgkin's lymphomas, Mauch PM, Armitage JO, Coiffier B, et al (eds), pp 613-627, Lippincott Williams&Wilkins, Philadelphia, 2004.
 
20) Jacomet C, Girard PM, Lebrette MG, et al:Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. AIDS 15:1725-1730, 1997.
PubMed

[23] 眼の周囲に発生するリンパ腫の治療

P.281 掲載の参考文献
1) Shikishima K, Kawai K, Kitahara K:Pathological evaluation of orbital tumours in Japan;analysis of a large case series and 1379 cases reported in the Japanese literature. Clinical&Experimental Ophthalmology 34:239-244, 2006.
PubMed
2) Ohtsuka K, Hashimoto M, Suzuki Y:high incidence of orbital malignant lymphoma in Japanese patients. Am J Ophthalmol 138:881-882, 2004.
PubMed
3) Nakata M, Matsuno Y, Katsumata N, et al:Histology according to the Revised European-American Lymphoma Classification significantly predicts the prognosis of ocular adnexal lymphoma Leuk Lymphoma 32:533-543, 1999.
 
4) Ferry JA, Fung CY, Zukerberg L, et al:Lymphoma of the ocularadnexa:A study of 353 cases. Am J Surg Pathol 31:170-184, 2007.
 
5) Jaffe ES, Harris NL, Stein H, et al:World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Heamatopoietic and Lymphoid Tissues, IARC press, Lyon, 2001.
 
6) Tanimoto K, Kaneko A, Suzuki S, et al:Primary Ocular Adnexal MALT Lymphoma;A Long-term Follow-up Study of 114 Patients. Jpn J Clin Oncol 37:337-344, 2007.
PubMed
7) Husain A, Roberts D, Pro B, et al:Meta-analyses of the association between Chlamydia psittaci and ocularadnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics. Cancer 110:809-815, 2007.
 
8) Ferreri AJ, Ponzoni M, Martinelli G, et al:Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa Haematologica 90:1578-1579, 2005,
PubMed
9) Dunbar SF, Linggood RM, Doppke KP, et al:COnjunctival lymphoma;results and treatment with a single anterior electron field. A lens sparing approach, Int J Radiat Oncol Biol Phys 19:249-257, 1990.
 
10) Emami B, Lyman J, Brown A, et al:Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109-122, 1991.
PubMed
11) Tsang RW, Gospodarowicz MK, Pintilie M, et al:Localized Mucosa-Associated Lymphoid Tissue Lymphoma Treated With Radiation Therapy Has Excellent Clinical Outcome. J Clin Oncol 21:4157-4164, 2003.
PubMed
12) Le QT, Eulau SM, George Tl, et al:Primary radiotherapy for localized orbital MALT lymphoma. Int J Radiat Oncol Biol Phys 52:657-663, 2002.
 
13) Isobe K, Kagami Y, Higuchi K, et al:A Multicenter Phase II Study of Local Radiation Therapy for Stage IEA Mucosa-Associated Lymphoid Tissue Lymphomas;A Preliminary Report from the Japan Radiation Oncology Group (Jarog) . Int J Radiat Oncol Biol Phys 69:1181-1186, 2007.
 
14) Bolek TW, Moyses HM, MarcusJr RB, et al:Radiotherapy in the management of orbital lymphoma. Int J Radiat Oncol Biol Phys 44:31-36, 1999.
 
15) Bessell EM, Henk JM, Whitelocke RA, et al:Ocular morbidity after radiotherapy of orbital and conjunctival lymphoma. Eye 1 (Pt 1):90-96, 1987.
 
16) Sasai K, Yamabe H, Dodo Y, et al:Non-Hodgkin's lymphoma ofthe ocularadnexa, Acta Oncol 40:485-490, 2001.
 
17) White W, Ferry J, Harris N, et al:Ocular adnexal lymphoma:A clinicopathologic study with identification of lymphomas of mucosa-associated lymphoid tissue type. Ophthalmology 102:1994-2006, 1995.
PubMed
18) Chao CKS, Lin H-s, Devineni VR, et al:Radiation therapy forprimary orbital lymphoma. Int J Radiat Oncol Biol Phys 31:929-934, 1995,
 
19) Baldini L, Blini M, Guffanti A, et al:Treatment and prognosis in a series of primary extranodal lymphomas of the ocular adnexa. Ann Oncol 9:779-781, 1998.
 
20) Cahill M, Barnes C, Moriarty P, et al:Ocular adnexal lymphoma-comparison of MALT lymphoma with other histological types. Br J Ophthalmol 83:742-747, 1999.
PubMed
21) Suh CO, Shim SJ, Lee SW, et al:Orbital marginal zone B-cell lymphoma of MALT;Radiotherapy results and clinical behavior. Int J Radiat Oncol Biol Phys 65:228-233, 2006.
PubMed
22) Uno T, Isobe K, Shikama N, et al:Radiotherapy for extranodal, marginal zone, B-cell lymphoma ofmucosa-associated lymphoid tissue originating in the ocular adnexa;a multi institutional, retrospective review of 50 patients. Cancer 98:865-871, 2003.
 
23) Lee JL, Kim MK, Lee KH, et al:Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue-type of the orbit and ocular adnexa. Ann Hematol 84:13-18, 2005.
 
24) Tsang RW, Gospodarowicz MK, Pintilie M, et al:stage I and II malt lymphoma;results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys 50:1258-1264, 2001,
 
25) Gordon KB, Char DH, Sagerman RH:Late effects of radiation on the eye and ocular adnexa, Int J Radiat Oncol Biol Phys 31:1123-1139, 1995.
PubMed

[24] 皮膚に発生するリンパ腫の治療

P.295 掲載の参考文献
1) Willemze R, Jaffe ES, Burg G, et al:WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-3785, 2005.
PubMed
2) Kim YH, Jensen RA, Watanabe GL, et al:Clinical stage I A (limited patch and plaque) mycosis fungoides;A long-term outcome analysis. Arch Dermatol 132:1309-1313, 1996.
 
3) Herrmann JJ, Roenigk HH Jr, Hurria A, et al:Treatment of mycosis fungoides with photochemo-therapy (PUVA);long-term follow-up. J Am Acad Dermatol 33:234-242, 1995.
 
4) Boztepe G, Sahin S, Ayhan M, et al:Narrowband ultraviolet B phototherapy to clear and maintain clearance in patients with mycosis fungoides. J Am Acad Dermatol 53:242-246, 2005.
PubMed
5) 長谷哲男, 岡澤ひろみ, 猪又直子, ほか:扁平浸潤期菌状息肉症に対するPUVAとInterferon-γ併用療法, 西日皮膚66:274-279, 2004,
 
6) Chiarion-Sileni V, Bononi A, Fornasa CV, et al:Phase II triai of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma Cancer 95:569-575, 2002.
 
7) Gniadecki R, Assaf C, Bagot M, et al:The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermato1157:433-440, 2007.
PubMed
8) 長谷哲男:放射線療法. 新・悪性リンパ腫アトラス, 瀧川雅浩, 岩月啓氏, 大島孝一, ほか (編), pp 188-192, 文光堂, 東京, 2006.
 
9) Jones GW, Hoppe RT, Glatstein E:Electron beam treatment for cutaneous T-cell lymphoma, Hematol Oncol Clin N Am 9:1057-1076, 1995.
 
10) Jones GW, Kacinski BM, Wilson LD, et al:Total skin electron radiation in the management of mycosis fungoides;Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol 47:364, 2002.
 
11) Heald P, ROok A, Perez M, et al:Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photo-chemotherapy. J Am Acad Dermatol 27:427-433, 1992.
 
12) Suchin KR, Cucchiara AJ, Gottleib SL, et al:Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy;a 14-year experience at a single institution. Arch Dermatol 138:1054-1060, 2002.
 
13) Duvic M, Apisarnthanarax N, Cohen DS, et al:Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 49:35-49, 2003.
PubMed
14) Kim YH, Willemze R, Pimpinelli N, et al:TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome;a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Reseach and Treatment of Cancer (EORTC) , Blood 110:479-484, 2007.
 
15) Bekkenk MW, Geelen FAMJ, van Voorst Vader PC, et al:Primary and secondary cutaneous CD30 lymphoproliferative dis-orders;a report from the Dutch Cutaneous Lymphoma Group on the longterm follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 95:3653-3661, 2000.
 
16) Vonderheid EC, Sajjadian A, Kadin ME, et al:Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoprolifera-tive disorders. J Am Acad Dermatol 34:470-480, 1996.
 
17) Schmuth M:Prognosis of lymphomatoid papulosis. The Oncologist 11:955-957, 2006.
PubMed
18) Go RS, Wester SM:Immunophenotypic and molecular features, clinical outcome, treatments, and prognostic factors associated with subcutaneous pannicul itis-like T-cell lymphoma;a systematic analysis of 156 patients reported in the literature. Cancer 101:1404-1413, 2004.
 
19) Senff NJ, Hoefnagel JJ, Jansen PM, et al:Reclassification of 300 primary cutaneous B-cell symphomas according to the new WHO-EORTC classification for cutaneous lymphomas;comparison with previous classfications and identification of prognostic makers. J Clin Oncol 25:1581-1587, 2007.
 
20) Kerl K, Prins J, Saurat JH, et al:Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab;report and follow-up of eight cases. Br J Dermatol 155:1197-1200, 2006.
 

[25] 骨に発生するリンパ腫の治療

P.304 掲載の参考文献
1) Oberling C:Les Reticulosarcomes et ies reticuloendotheliosarcomes de la moelle osseuse (sarcomas d:Ewing) . Bull Assoc Fr Etude Cancer 17:259-296, 1928,
 
2) Parker F Jr., Jackson H Jr.:Primary reticulum cell sarcoma of bone. Surg Gynecol Obstet 68:45-53, 1939.
 
3) Freeman C, Berg J, Cutlers:Occurrence and prognosis of extranodal lymphomas. Cancer 29:252-260, 1972.
 
4) Isaacson P, Norton A:Extranodal lymphoma in miscellaneous sites. Extranodal Lymphomas, Isaacson P, Norton A (eds), pp289-298, Churchill Livingstone, New York, 1994.
 
5) Fletcher C, Unni K, Mertens F:Pathology and Genetics of Tumours of Soft Tissue and Bone. World Health Organization Classification of Tumours, pp306-308, International Agency for Research on Cancer, Lyon, 2002.
 
6) Heyning FH, Hogendoorn PCW, Kramer MHH, et al:Primary non-Hodgkin's lymphoma of bone;a clinicopathological investigation of 60 cases. Leukemia 13:2094-2098, 1999.
 
7) Zinzani PL, Carrillo G, Ascani S, et al:Primary bone lymphoma;experience with 52 patients, Haematologica 88:280-285, 2003,
PubMed
8) Horsman JM, Thomas J, Hough R, et al:Primary bone lymphoma;a retrospective analysis. Int J Oncol 28:1571-1575, 2006.
PubMed
9) Beal K, Allen L, Yahalom J:Primary bone lymphoma;treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer 106:2652-2656, 2006.
PubMed
10) Ramadan KM, Shenkier T, Sehn LH, et al:A clinicopathological retrospective study of 131 patients with primary bone lymphoma:apopulation-based study of successively treated cohorts from the British Columbia Cancer Agency. Ann Oncol 18:129-135, 2007.
 
11) Maruyama D, Watanabe T, Beppu Y, et al:Primary bone lymphoma;a new and detailed characterization of 28 patients in a single-institution study. Jpn J Clin Oncol 37:216-223, 2007.
 
12) International Non-Hodgkin's Lymphoma Prognostic, Factors Project:A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993.
 
13) Ostrowski ML, Unni KK, Banks PM, etal:Malignant lymphoma of bone. Cancer 58:2646-2655, 1986.
PubMed
14) Ueda T, Aozasa K, Ohsawa M, et al:Malignant lymphomas of bone in Japan, Cancer 64:2387-2392, 198115) Bayrakci K, Yildiz Y, Saglik Y, et al:Primary lymphoma of bones. Int Orthop 25:123-126, 2001.
 
16) Stein ME, Epelbaum R, Zaidan J, et al:Excellent long-term survival in patients with early-stageprimary bone lymphoma treated with doxorubicin-based chemotherapy and local radiotherapy. Am J Clin Oncol 25:603-605, 2002,
 
17) Lewis VOI Primus G, Simon MA, et al:Oncologicoutcomes of primary lymphoma of bone in adults. Clin Orthop Relat Res 415:90-97, 2003.
 
18) Mulligan ME, McRae GA, Murphy MD:Imaging features of primary lymphoma of bone. Am J Roentgenol 173:1691-1697, 1999.
 
19) Mengiardi B, Honegger H, Hodler J, et al:Primary lymphoma of bone;MRI and CT characteristics during and after successful treatment. Am J Roentgenol 184:185-192, 2005.
 
20) Baar J, Burkes RL, Gospodarowicz M:Primary non-Hodgkin's lymphoma of bone. Semin Oncol 26:270-275, 1999.
PubMed
21) Lewis SJ, Bell RS, Fernandes BJ, et al:Malignant lymphoma of bone. Can J Surg 37:43-49, 1994.
PubMed
22) Jelinek JS, Murphy MD, Welker JA, et al:Diagnosis of primary bone tumors with image-guided percutaneous biopsy;experience with 110 tumors. Radiology 223:731-737, 2002.
 
23) Leval L, Braaten KM, Ancukiewicz M, et al:Diffuse large B-cell lymphoma of bone;An analysis of differentiation-associated antigens with clinical correlation. Am J Surg Pathol 27:1269-1277, 2003.
 
24) Buchmann I, Reinhardt M, Elsner K, et al:2-(fluorine-18) fluoro-2-deoxy-D-giucose positron emission tomography in the detection and staging of malignant lymphoma:A bicenter trial Cancer 91:889-899, 200125) Moog F, Bangerter M, Diederichs CG, et al:Extranodal malignant lymphoma;detection with FDG PET versus CT. Radiology 206:475-481, 1998.
 
26) Moog F, Kotzerke J, Reske SN:FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma, J Nucl Med 40:1407-1413, 1999.
PubMed
27) Wang CC, Fleischli DJ:Primary reticulum cell sarcoma of bone;With emphasis on radiation therapy. Cancer 22:994-998, 1968.
PubMed
28) Rathmell AJ, Gospodarowicz MK, Sutcliffe SB, et al:Localized lymphoma of bone;prognostic factors and treatment recommendations. The Princess Margaret Hospital Lymphoma Group. Br J Cancer 66:603-606, 199229) Fidias P, Spiro I, Sobczak ML, et al:Long-term results of combined modality therapy in primary bone lymphomas. Int J Radiat Oncol Biol Phys 45:1213-1218, 1999.
 
30) Bacci G, Picci P, Bertoni F, et al:Primary non-Hodgkin's lymphoma of bone;Results in 15 patientstreated by radiotherapy combined with systemic chemotherapy. Cancer Treat Rep 66:1859-1862, 1982.
 
31) Israel O, Mekel M, Bar-Shalom R, et al:Bone lymphoma;67Ga scintigraphy and CT forprediction of outcome after treatment. J Nucl Med 43:1295-1303, 2002.
 
32) Juweid ME, Stroobants S, Hoekstra OS, et al:Use of positron emission tomography for response assessment of lymphoma;consensus of the imaging subcommittee of International Harmonization Project in lymphoma J Clin Oncol 25:571-578, 2007.
 
33) Cheson BD, Pfistner B, Malik E, et al:Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007.
 
34) Park YH, Kim S, Lee SS, et al:Clinical impact of whole-body FDG-PET for evaluation of response and therapeutic decision-making of primary lymphoma of bone. Ann Oncol 16:1401-1402, 2005.
 

[26] 再発、再燃悪性リンパ腫の救援化学療法

P.318 掲載の参考文献
1) Hamlin PA, Zelenetz AD, Kewalramani T, et al:Age-adjusted International Prognostic Index predicts autologous stem-cell transplantation outcome for patients with relapsed or primary refractory difffuse large B-cell lymphoma. Blood 102:1989-1996, 2003.
PubMed
2) Sehn LH, Berry B, Chhnabhai M, etal:The revised International Prognostic Index (R-IPD is a better predictor of outcome than the standard IPl for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857-1861, 2007.
 
3) Philip T, Gugliemi C, Hagenbeek A, et al:Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of salvage chemotherapy-sensitive non Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995.
 
4) Schmitz N, Pfistner B, Sextor M, et al:Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease. Lanset 359:2065-2071, 2002.
 
5) Velasquez WS, Cabanillas F, Salvador P, et al:Effective salvage chemotherapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP) . Blood 71:117-122, 1988.
PubMed
6) Velasquez WS, McLaughlin P, Tucker S, et al:ESHAP;an effective chemotherapy regimen in refractory and relapsing lymphoma;a 4-year follow-up study. J Clin Oncol 12:1169-1176, 1994.
PubMed
7) Ogura M, Kagami Y, Taji H, et al:Phase I/II study of new salvage therapy (CHASE) for refractory or relapsed malignant lymphoma. Int J Hematol 77:503-511, 2003.
PubMed
8) Maskowitz CH, Bertino JR, Glassman JR, et al:lfosfamide, carboplatin, and etoposide:a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 17:3776-3785, 1999.
 
9) Wilson WH, Bryant G, Barts S, et al:EPOCH Chemotherapy:Toxicity and efficacy in relapsed and refractory non Hodgkin's lymphoma. J Clin Oncol 11:1573-1582, 1993.
 
10) Chao NJ, Rosenberg SA, Horning SJ:CEPP (B);An effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. Blood 76:1293-1298, 1990.
PubMed
11) Coleman M, Ruan J, Furman RR, et al:Oral combination chemotherapy for refractory/relapsed lymphoma with the PEP-C (C3) regimen (daily predonisone, etposide, procarbazine, cyclophos-phamide);Low-dose continuous metoronic multidrug therapy. J Clin Oncol 25:457s, 2007.
 
12) Sugiyama K, Omachi K, Fujiwara K, et al:Irinotecan hydorocloride for the treatment of recurrent and refractory non-Hodgkin lymphoma. Cancer 94:594-600, 2002.
PubMed
13) Kewalramani T, Zelenetz AD, Nimer SD, et al:Rituximab and ICE as second-line therapy before autologous stem-cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103:3684-3688, 2004.
PubMed
14) Hoerr AL, Gao F, Hidalgo J, et al:Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkins lymphoma J Clin Oncol 22:4561-4566, 2004.
PubMed
15) Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse Iarge B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomization to maintenance treatment with rituximab or not;an update of the CORAL study. Ann Oncol 17 (Suppl 4):iv 31-iv 32, 2006
 

[27] 悪性リンパ腫の自家造血幹細胞移植併用大量化学療法: 適切な施行対象と施行時期

P.331 掲載の参考文献
1) 日本造血細胞移植学会:造血幹細胞移植の適応ガイドライン;悪性リンパ腫.JSHCT mongraph 6:48, 2002.
 
2) 田野崎隆二:悪性リンパ腫;自家造血幹細胞移植の現状と同種移植の適応, 内科88:449, 2001.
 
3) 田野崎隆二:造血幹細胞移植の適応と治療成績 (悪性リンパ腫) . 日本内科学会雑誌94:1322, 2005,
 
4) Barosi G, Carella A, Lazzarino M, et al:Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas;practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 90:1236, 2005.
 
5) Van Besien K:The evolving role of autologous and aliogeneic stem cell transplantation infollicular lymphoma. Blood Rev 20:235, 2006.
 
6) Hasenclever D, Diehl V, Armitage JO, et al:for the international prognostic factors project on advanced Hodgkin's disases;A prognostic score for advanced Hodgkin's disease. N Engl J Med 339:1506, 1998.
 
7) Federico M, Bellei M, Brice P, et al:EBMT/GISL/ANZLG/SFGM/GELA intergroup HDOI Trial;High-dose therapy and autoiogous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 21:2320, 2003.
 
8) Schmitz N, Pfistner B, Sextro M, et al:Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemaopoietic stem cell transplantation for relapsed chemosensitive Hodgkin's disease;a randomized trial. Lancet 359:2065, 2002.
 
9) Shipp MA, Abeloff MD, Antman KH, et al:International consensus conference on high-dose therapy with hematopoietic stem cell transplantationin aggressive non-Hodgkin's lymphomas:Report of the jury. J Clin Oncol 17:423, 1999.
 
10) Barosi G, Carella A, Lazzarino M, et al:Management of nodal diffuse large B-cell lymphomas;practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 91:96, 2006.
 
11) The International Non-Hodgkin's Lymphoma Prognostic Factors Project:A predictive model for aggressive non-Hodkgkin:s lymphoma. N Engl J Med 329:987, 1993.
 
12) Philip T, Guglieimi C, Hagenbeek A, et al:Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540, 1995.
 
13) Rodriguez J, Munsell M, Yazji S, et al:Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 19:3766, 2001.
 
14) Dogan A, Attygalle AD, Kyriakou C:Review;Angioimmunoblastic T-cell lymphoma Br J Haematol 121:681, 2003.
PubMed

[28] 悪性リンパ腫の同種造血幹細胞移植

P.348 掲載の参考文献
1) Corradini P, Dodero A, Farina L, et al:Allogeneic stem cell transpiantation following reduced-intenslty conditioning can Induce durable clinical and molecular remissions In relapsed lymphomas;pre-transplant disease status and histotype heavily influence outcome. Leukemia 21:2316-2323, 2007.
 
2) Kusumi E, Kami M, Kanda Y, et al:Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma;a retrospective survey of 112 adult patlents in Japan. Bone Marrow Transplant 36 205-213, 2005.
 
3) Lowsky R, Takahashi T, Liu YP, et al Protective conditioning for acute graft-versus-host disease N Engl J Med 353:1321-1331, 2005
PubMed
4) Baron F, Storb R, Storer BE, et al:Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 24:4150-4157, 2006.
PubMed
5) Kim SW, Tanimoto TE, Hirabayashi N, et al:Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma;a nationwide survey in Japan. Blood 108:382-389, 2006.
PubMed
6) Khouri IF, Saliba RM, Hosing CM, et al:Autologous stem cell (AUTO) vs non-myeloablative allogeneic transplantation (NMT) after high-dose rituximab (HDR)-containing conditioning regi-mens for relapsed chemosensitve follicular lymphoma (FL) . Blood (ASH Annual Meeting Abstracts) 106:48, 2005.
 
7) Corradini P, Dodero A, Zallio F, et al:Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning fol|owed by allogeneic transplan-tation of hematopoietic cells. J Clin Oncol 22:2172-2176, 2004.
 
8) Le Gouill S, Milpied N, Buzyn A, et al:Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults;a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 26:2264-2271, 2008.
PubMed
9) Peggs KS, Hunter A, Chopra R, et al:Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 365:1934-1941, 2005.
PubMed
10) Devetten MP, Hari P, Carerras J, et al:Unrelated donor nonmyeloablative/reduced intensity (NST/ RIC) hematopoietic stem cell transplantation (HCT) for patients with relapsed and refractory Hodgkin's lymphoma (HL) . Blood (ASH Annual Meeting Abstracts) 108:601, 2006.
 
11) Gopal AK, Rajendran JG, Pagel JM, et al:A Phase II trial of 90Y-ibritumomab tiuxetan-based reduced intensity allogeneic peripheral blood stem cell (PBSC) transplantation for relapsed CD20 +B-cell non-Hodgkin's lymphoma (NHL) . Blood (ASH Annual Meeting Abstracts) 108:316, 2006.
 
12) Khouri IF, SalibaRM, Hosing C, et al:Efficacy and safety of yttrium 90 (90Y) ibritumomab tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-Hodgkin's lymphoma (NHL) . Bfiood (ASH Annual Meeting Abstracts) 108:315, 2006.
 
13) Andersson BS, Kashyap A, Gian V, et al:Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation;a phase II study. Biol Blood Marrow Transplant 8:145-54, 2002.
PubMed
14) McSweeney PA, Niederwieser D, Shizuru JA, et al:Hematopoietic cell transplantation in older patients with hematologic malignancies;replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390-3400, 2001,
PubMed
15) Slavin S, Nagler A, Naparstek E, et al:Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756-763, 1998.
PubMed
16) Giralt S, Estey E, Albitar M, et al:Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy;harnessing graft-versus-leukemia without myeloablative therapy. Blood 89:4531-4536, 1997.
PubMed
17) Saito A, Kami M, Mori S, et al:Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan. Am J Hematol 82:873-880, 2007.
PubMed
18) McDonald GB, Hinds MS, Fisher LD, et al:Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation;acohort study of 355 patients. Ann Intern Med 118:255-267, 1993.
 

[29] 抗がん剤治療の副作用とその対策

P.360 掲載の参考文献
1) Igarashi T, Kobayashi Y, Ogura M, et al:Factor affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab;a Japanese phase II study. Ann Oncol 13:928-943, 2002.
PubMed
2) Kunkel L, Wong A, Maneatis T, et al:Optimizing the use of Rituximab for treatment of B-ce.non-Hodgkin's lymphoma;A benefit-risk update. Semin Oncol 27:53-61, 2000.
 
3) Kris MG, Hesketh PJ, Somerfield MR, et al:American society of clinical oncology guideline for antiemetics in oncology;Update 2006.J Clin Oncol 24:2932-2947, 2006.
 
4) Hirano M, Okamoto M, Maruyama F, et al:Alternating non-cross-resistant chemotherapy for non-Hodgkin's lymphoma of intermediate-grade and high-grade malignancy;A pilot study. Cancer 69:772-777, 1992.
PubMed
5) Smith TJ, Khatcheressian J, Lyman GH, et al:2006 update of recommendations for the use of white blood cell growth factors;An evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205, 2006
PubMed
6) Kuderer NM, Dale DC, Crawford J, et al:Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy:a systemic review. J Clin Oncol 25:3158-3167, 2007.
PubMed
7) Hughes WT, Armstrong D, Bodey GP, et al:2002 Guideline for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730-751, 2002.
PubMed
8) Masaoka T:Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan;executive Summary. Clin Infect Dis 39 (Suppl 1):S49-S52, 2004.
 
9) Walsh TJ, Pappas P, Winston DJ, et al:Voriconazole compared with liposomal amphotericin B for ampirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346:225-234, 2002.
 
10) Rizzo JD, Lichtin AE, Woolf SH, et al:Use of epoetin in patients with cancer;evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20:4083-4107, 2002.
 
11) Schiffer CA, Anderson KC, Bennett CL, et al:Platelet transfusion for patients with cancer;clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1519-1538, 2001.
 
12) Stephen TS, Linda SE, Dorothy K, et al:Perspective on cancer therapy-induced mucosal injury. Cancer 100:1995-2015, 2004.
 
13) Benson III AB, Ajani A, Catalano RB, et al:Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22:2918-2926, 2004.
 
14) Meadors M, Floyd J, Perry MC:Pulmonary toxicity of chemotherapy. Semin Oncol 22:2918-2926, 2004.
 
15) Krischer JP, Epstein S, Cuthbertson DD, et al:Clinical cardiotoxicity following anthracycline treatment for childhood cancer;the Pediatric Oncology Group experience. J Clin Oncol 15:1544-1552, 1997.
PubMed
17) Goldberg MA, Antin JH, Guinan EC, et al:Cyclophosphamide cardiotoxicity;an analysis of dosing as a risk factor. Blood 68:1114-1118, 1986.
PubMed

[30] 悪性リンパ腫治療中のB型肝炎ウイルス再活性化とその対策

P.370 掲載の参考文献
1) Rehermann B, Ferrari C, Pasquinelli C, et al:The hepatitis B virus persists for decades after patients:recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2:1104-1108, 1996.
PubMed
2) Yeo W, Johnson PJ:Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43:209-220, 2006.
PubMed
3) Hui CK, Cheung VVVV, Zhang HY, et al:Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131:59-68, 2006.
 
4) Lau GK, Yiu HH, Fong DY, et al:Early is superlor to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125:1742-1749, 2003.
PubMed
5) Lok AS, Liang RH, Chiu EK, et al:Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy;Report of a prospective study. Gastroenterology 100:182-188, 1991.
PubMed
6) Westhoff TH JF, Schmittel A, Stoffler-Meilicke M, et al:Fatal hepatitis B virus reactivation by anescape mutant following rituximab therapy. Blood 102:1930, 2003.
 
7) Dervite I, Hober D, Morel P:Acute hepatitis B in a patient with antibodies to hepatitis B surfaceantigen who was receiving rituximab. N Engl J Med 344:68-69, 2001.
 
8) Cheng AL, Hsiung CA, Su IJ, et al:Steroid-free chemotherapy decreases risk of hepatitis B virus HBV) reactivation in HBV-carriers with lymphoma. Hepatology 37:1320-1328, 2003.
PubMed
9) Dhedin N, Douvin C, Kuentz M, et al:Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation;aretrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 66:616-619, 1998.
 
10) Locasciulli A, Bruno B, Alessandrino EP, et al:Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV) /hepatitis C virus (HCV) positive recipients;aretrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant 31:295-300, 2003.
 
11) Yeo W, Chan PK, Zhong S, et al:Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy;aprospective study of 626 patients with identification of risk factors. J Med Virol 62:299-307, 2000.
 
12) Yeo W, Zee B, Zhong S, et al:Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy, Br J Cancer 90:1306-1311, 2004.
PubMed
13) Lau GK, Liang R, Chiu EK, et al:Hepatic events after bone marrow transplantation in patients withhepatitis B infection;acase controlled study. Bone Marrow Transplant 19:795-799, 1997.
 
14) Seth P, Alrajhi AA, Kagevi I, et al:Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transpiant 30:189-194, 2002.
 
15) Yeo W, Chan PK, Ho WM, et al:Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy, J Clin Oncol 22:927-934, 2004.
PubMed
16) 全薬工業社内資料
 
17) Umemura T, Kiyosawa K:Fatal HBV reactivation in a subject with anti-HBs and anti-HBc. Intern Med 45:747-748, 2006.
 
18) Hui CK, Sun J, Au WY, et al:Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 42:813-819, 2005.
 
19) 楠本 茂, 田中靖人, 溝上雅史, ほか:B型肝炎の自然経過と悪性リンパ腫治療における再活性化のリスク. 血液・腫瘍科54:737-742, 2007.
 
20) 厚生労働科学研究費補助金肝炎等克服緊急対策研究事業 (肝炎分野) 研究班:B型慢性肝炎の治療ガイドライン. 2006.
 
21) Shinkai N, Tanaka Y, Orito E, et al:Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection. Hepatol Res 36:272-276, 2006,
PubMed

[31] 悪性リンパ腫治療後の晩期障害と二次癌

P.381 掲載の参考文献
1) Benyunes MC, Multani PS, Saunders A:Neutropenia in patients treated with Rituximab. Engl J Med 348 (26):2691-2694, 2003.
 
2) Tsutsumi Y, Kawamura T, Saitoh S, et al:Hepatitis B virus reactivation in a case of non-Hodgkin:lymphoma treated with chemotherapy and Rituximab:Necessary of prophylaxis for hepatitis Bvirus reactivation in Rituximab therapy. Leukemia&Lymphoma 45:627-629, 2004.
 
3) Benyunes MC, Multani PS, Saunders A:Interstitial pneumonitis related to Rituximab therapy. Engl J Med 348 (26):2690-2691, 2003.
 
4) Arseneau JC, Sponzo RW, Levin DL, et al:Nonlymphomatous malignant tumors complicating Hodgkin's disease;Possible association with intensive therapy. N Engl J Med 287:1119-1122, 1972.
PubMed
5) Ng Ak, Bermardo MP, Weller E, et al:Longterm survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or yonger. J Clin Oncol 20:2101-2108, 2002.
 
6) Aleman BM, vanden Belt-Dusebout AW, Klokman WJ, et al:Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21:3431-3439, 2003.
 
7) Brunning RD, et al:Acute myeloid leukemias and myelodysplastic syndromes, therapy related. World health organization classification of tumors, Pathology and genetics, Tumor of Haematopoietic and lymphoid tissues, Jaffe ES, et al (eds), pp89-91, IARC press, Lyon, 2001.
 
8) Han-Ming Joseph Lin, Michael A Teitell:Second malignancy after treatment of pediatric Hodgkin disease. J Pediotr Hematol Oncol 27:28-36, 2005.
PubMed
9) Swerdlow AJ, et al:Risk of second primary cancers after Hodgkin's disease by type of treatment;analysis of 2826 patients in the British National Lymphoma Investigation. Br Med J 304:1137-1143, 1992
 
10) Franklin J, Pluetschow A, Paus M, et al:Second malignancy risk associated with treatment of Hodgkin's lymphoma;meta-analysis of the randomised trials. Ann Oncol 17:1749-1760, 2006.
PubMed
11) Rosenberg SA:The treatment of Hodgkin's disease. Ann Oncol 5 (suppl 2):17-21, 1994.
 
12) Hancock SL, Tucker MA, Hoppe RT:Breast cancer after treatment of Hogkin:s disease. J Natl Cancer Inst 85:25-31, 1993.
 
13) Takeyama K, Seto M, Uike N, et al:Therapy-related leukemia and myelodysplastic syndrome;a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors. Int J Hematol 71:144-152, 2000.
PubMed
14) Pedersen-Bjergaard J, Andersen MK, Christiansen DH, et al:Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplanta-tion. Blood 95:3273-3279, 2000.
 
15) Micallef IN, Lillington DM, Apostolidis J, et al:Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 18:947-955, 2000.
PubMed
16) Shimada K, Yokozawa T, Atsuta Y, et al:Solid tumors after hematopoietic stem cell transplantation in Japan;incidence, risk factors and prognosis. Bone Marrow Transplantation 36:115-121, 2005.
PubMed
17) Cheson BD, Vena DA, Barrett J, et al:Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 17:2454-2460, 1999.
PubMed
18) Morrison VA, Rai KR, Peterson BL, et al:Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with Fludarabine and Chlorambucil;results of an intergroup study, Cancer and leukemia group B 9011.J Clin Oncol 20:3878-3884, 2002.
 
19) Alan AB:Fludarabine-related myeloid leukemia JCO 19:1-21 (author reply 3709-3710), 2003.
 

[32] 悪性リンパ腫に対して開発中の新薬

P.393 掲載の参考文献
1) Fisher RI, LeBlanc M, Press OW, et al:New treatment options have changed the survival of patients wih follicular lymphoma J Clin Oncol 23:8447-8452, 2005.
 
2) Feugier P, Van Hoof A, Sebban C, et al:Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma;astudy by the Groupe d:Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126, 2005.
 
3) Tobinai K, Watanabe T, Ogura M, et al:Phase II study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin lymphoma. J Clin Oncol 24:174-180, 2006.
PubMed
4) Niwa R, Hatanaka S, Shoji-Hosaka E, et al:Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaR IIIa functional polymorphism. Clin Cancer Res 10:6248-6255, 2004.
 
5) Cartron G, Dacheux L, Salles G, et al:Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in lgG Fc receptor Fc-gamma-R IIIa gene. Blood 99:754-758, 2002.
 
5) Stein R, Qu z, Chen S, et al:Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 10:2868-2878, 2004.
PubMed
6) Morshhauser F, Leonard JP, Coiffier B, et al:Phase I/II results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in NHL. Proc Am Soc Clin Oncol 24:7530 (abstract), 2006.
 
7) Coiffier B, Lepretre S, Pedersen LM, et al:Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocyticleukemia;aphase 1-2 study. Blood 111:1094-1100, 2008.
PubMed
8) Leonard JP, Coleman M, Ketas JC, et al:Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 21:3051-3059, 2003.
PubMed
9) Leonard JP, Coleman M, Ketas JC, et al:Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma;phase I/II clinical trial results. Clin Cancer Res 10:5327-5334, 2004.
PubMed
10) Leonard JP, Coleman M, Ketas J, et al:Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 23:5044-5051, 2005.
PubMed
11) DiJoseph JF, Armeilino DC, Boghaert ER, et al:Antibody-targeted chemotherapy with CMC-544;a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103:1807-1814, 2004.
 
12) Keating MJ, Flinn I, Jain V, et al:Therapeutic role of alemtuzumab (Campath-IH) in patients who have failed fludarabine;resuits of a large international study. Biood 99:3554-3561, 2002.
 
13) Lundin J, Kimby E, Bjorkholm M, et al:Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-IH) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL) . Blood 100:768-773, 2002.
 
14) Gallamini A, Zaja F, Patti C, et al:Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma;results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110:2316-2323, 2007.
PubMed
15) Peleg AY, Husain S, Kwak EJ, et al:Opportunistic infections in 5470rgan transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 44:204-212, 2007.
PubMed
16) Rodig SJ, Abramson JS, Pinkus GS, et al:Heterogeneous CD52 expression among hematologic neoplasms;implications for the use of alemtuzumab (CAMPATH-1H) . Clin Cancer Res 12:7174-7179, 2006.
PubMed
17) Rummel MJ, Al-Batran SE, Kim S-Z, et al:Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 23:3383-3389, 2005.
 
18) Carducci MA, Musib L, Kies MS, et al:Enzastaurin (LY317615), an oral PKCbeta (PKCbeta) inhibitor, in patients with advanced cancer;a phase I dose escalation and pharmacokinetic study. J Clin Oncol 24:4092-4099, 2006.
 
19) Robertson MJ, Kahl BS, Vose JM, et al:Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 25:1741-1746, 2007.
PubMed
20) Ishida T, Ueda R:CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 97:1139-1146, 2006.
PubMed
21) Olsen EA, Kim YH, Kuzel TM, et al:Phase ll b multicenter trial of vorinostat in patients with persistent, progressive, ortreatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25:3109-3115, 2007.
 
22) Balakrishnan K, Nimmanapalli R, Ravandi F, et al:Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood 108:2392-2398, 2006.
PubMed
23) O'Connor OA, Hamlin PA, Portlock C, et al:Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in adiversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 139:425-428, 2007.
 

書評

最近チェックした商品履歴

Loading...